CA2347891A1 - Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics - Google Patents
Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics Download PDFInfo
- Publication number
- CA2347891A1 CA2347891A1 CA002347891A CA2347891A CA2347891A1 CA 2347891 A1 CA2347891 A1 CA 2347891A1 CA 002347891 A CA002347891 A CA 002347891A CA 2347891 A CA2347891 A CA 2347891A CA 2347891 A1 CA2347891 A1 CA 2347891A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- group
- iron
- excipient
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 239000006041 probiotic Substances 0.000 title claims abstract description 49
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 49
- 239000011785 micronutrient Substances 0.000 title claims abstract description 46
- 235000013369 micronutrients Nutrition 0.000 title claims abstract description 46
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 35
- 235000019722 synbiotics Nutrition 0.000 title claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 63
- 235000013305 food Nutrition 0.000 claims abstract description 56
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- 230000000529 probiotic effect Effects 0.000 claims abstract description 27
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 21
- 230000036039 immunity Effects 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims abstract description 12
- 230000002708 enhancing effect Effects 0.000 claims abstract description 11
- 239000005022 packaging material Substances 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 219
- 229910052742 iron Inorganic materials 0.000 claims description 102
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 53
- 239000011701 zinc Substances 0.000 claims description 35
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 33
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 32
- 239000011719 vitamin A Substances 0.000 claims description 32
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 31
- 235000019155 vitamin A Nutrition 0.000 claims description 31
- 229940045997 vitamin a Drugs 0.000 claims description 31
- 229910052725 zinc Inorganic materials 0.000 claims description 30
- 235000016804 zinc Nutrition 0.000 claims description 29
- 235000014633 carbohydrates Nutrition 0.000 claims description 19
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims description 10
- 241000186000 Bifidobacterium Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 7
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 239000001993 wax Substances 0.000 claims description 5
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 4
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000832 lactitol Substances 0.000 claims description 4
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 4
- 229960003451 lactitol Drugs 0.000 claims description 4
- 235000010448 lactitol Nutrition 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 239000008173 hydrogenated soybean oil Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 241001468229 Bifidobacterium thermophilum Species 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 240000001929 Lactobacillus brevis Species 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 241001134659 Lactobacillus curvatus Species 0.000 claims description 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 2
- 241000438617 Schedorhinotermes intermedius Species 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 2
- 229960000511 lactulose Drugs 0.000 claims description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims 1
- 244000057717 Streptococcus lactis Species 0.000 claims 1
- 235000014897 Streptococcus lactis Nutrition 0.000 claims 1
- WOYYTQHMNDWRCW-JGWLITMVSA-N [(2r,3r,4r,5s)-2,3,4,5-tetrahydroxy-6-phosphonooxyhexyl] dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)COP(O)(O)=O WOYYTQHMNDWRCW-JGWLITMVSA-N 0.000 claims 1
- 229960003284 iron Drugs 0.000 description 97
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 43
- 235000005911 diet Nutrition 0.000 description 30
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 27
- 208000007502 anemia Diseases 0.000 description 27
- 230000037213 diet Effects 0.000 description 27
- 239000011773 ferrous fumarate Substances 0.000 description 27
- 235000002332 ferrous fumarate Nutrition 0.000 description 27
- 229960000225 ferrous fumarate Drugs 0.000 description 27
- 102000001554 Hemoglobins Human genes 0.000 description 19
- 108010054147 Hemoglobins Proteins 0.000 description 19
- 206010012735 Diarrhoea Diseases 0.000 description 18
- 229960005070 ascorbic acid Drugs 0.000 description 18
- 239000011668 ascorbic acid Substances 0.000 description 18
- 235000010323 ascorbic acid Nutrition 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 102000008857 Ferritin Human genes 0.000 description 12
- 108050000784 Ferritin Proteins 0.000 description 12
- 238000008416 Ferritin Methods 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 239000011790 ferrous sulphate Substances 0.000 description 11
- 235000003891 ferrous sulphate Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 235000013339 cereals Nutrition 0.000 description 8
- 210000000987 immune system Anatomy 0.000 description 8
- 201000004792 malaria Diseases 0.000 description 8
- 239000013589 supplement Substances 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 208000002720 Malnutrition Diseases 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 150000002506 iron compounds Chemical class 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 235000015872 dietary supplement Nutrition 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 235000000824 malnutrition Nutrition 0.000 description 6
- 230000001071 malnutrition Effects 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 208000015380 nutritional deficiency disease Diseases 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 4
- 238000011872 anthropometric measurement Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- -1 fatty acid esters Chemical class 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 244000005709 gut microbiome Species 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000000737 periodic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960000342 retinol acetate Drugs 0.000 description 4
- 235000019173 retinyl acetate Nutrition 0.000 description 4
- 239000011770 retinyl acetate Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000011670 zinc gluconate Substances 0.000 description 4
- 235000011478 zinc gluconate Nutrition 0.000 description 4
- 229960000306 zinc gluconate Drugs 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000011706 ferric diphosphate Substances 0.000 description 3
- 235000007144 ferric diphosphate Nutrition 0.000 description 3
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 3
- 229940036404 ferric pyrophosphate Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 206010022971 Iron Deficiencies Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000007248 cellular mechanism Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 244000000021 enteric pathogen Species 0.000 description 2
- 235000021112 essential micronutrients Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008881 mucosal defense Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000135 prohibitive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 150000003899 tartaric acid esters Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000000724 thymus hormone Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000032529 Accidental overdose Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031856 Haemosiderosis Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- OOIOHEBTXPTBBE-UHFFFAOYSA-N [Na].[Fe] Chemical compound [Na].[Fe] OOIOHEBTXPTBBE-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000741 diarrhetic effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002256 epithelial attachment Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007540 host microbe interaction Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- WBJZTOZJJYAKHQ-UHFFFAOYSA-K iron(3+) phosphate Chemical compound [Fe+3].[O-]P([O-])([O-])=O WBJZTOZJJYAKHQ-UHFFFAOYSA-K 0.000 description 1
- 229910000399 iron(III) phosphate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000020190 lactose-free milk Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 235000013384 milk substitute Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000020783 nutrient-dense food Nutrition 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 235000013606 potato chips Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008132 psychomotor development Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000003044 randomized block design Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- MKWYFZFMAMBPQK-UHFFFAOYSA-J sodium feredetate Chemical compound [Na+].[Fe+3].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MKWYFZFMAMBPQK-UHFFFAOYSA-J 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000021195 test diet Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000020797 vitamin A status Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229940091251 zinc supplement Drugs 0.000 description 1
- HJSYJHHRQVHHMQ-TYYBGVCCSA-L zinc;(e)-but-2-enedioate Chemical compound [Zn+2].[O-]C(=O)\C=C\C([O-])=O HJSYJHHRQVHHMQ-TYYBGVCCSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A composition useful for enhancing general immunity is disclosed. The composition includes one or more micronu-trients, one or more compounds selected from the group of a prebiotic, probiotic. and synbiotic, and lipid-based or carbohydrate-based excipient. Use of this composition to enhance general immunity of the composition is provided. A method of enhancing the general immunity of a mammal is provided, comprising the steps of removing a composition comprising micro-encapsulated micronutrient granules, a substance selected from the group of a prebiotic, probiotic or synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient from packaging material; adding a therapeu-tically effective amount of said composition to a food, and administering the food to said mammal.
Description
wo oms~ia PcricAOO~oo~no COMPOSITION COMPRISING MICRONUTRIENTS IN COMBINATION WITH PREBIOTICS, PROBIOTICS. AND/OR SYNBIOTICS
Field of the Invention The present invention relates to supplements for enhancement of the immune system.
More particularly, the present invention relates to compositions combining micronutrients, probiotics, prebiotics, and synbiotics which are especially useful for enhancement of the immune system.
Background of the Invention Proper nutrition is critical to the development of an effective immune system and enhancement of the natural imrnunosurveillance immune effector mechanism. This enhancement could be mediated either by increasing the frequency and absolute numbers of effector cells that carry out such function or by enhancement of the cellular mechanisms by which such effector cells mediate their function.
The clinical association of particular importance is between malnutrition and an individual's ability to respond to infectious micro-organisms or their antigenic constituents. Mechanisms by which nutrition affects immunity include reduced phagocytic activity and decreased leukocyte proliferation which, respectively, result in less vigorous microbial elimination and poor clonal expansion of microbe-specific lymphocytes. In addition, cell cycle, transcription regulation, antibody production, cytokine secretion and anti-oxidant protection may also be altered. Thus, the immune problems related to nutritional deficiencies vary from increased opportunistic infections to suboptimal responses following vaccination. In such cases dietary supplementation of micronutrients is likely to enhance immune function.
SUBSTITUTE SHEET (RULE26) wo omsm4 PcrrcAOOroo~o
Field of the Invention The present invention relates to supplements for enhancement of the immune system.
More particularly, the present invention relates to compositions combining micronutrients, probiotics, prebiotics, and synbiotics which are especially useful for enhancement of the immune system.
Background of the Invention Proper nutrition is critical to the development of an effective immune system and enhancement of the natural imrnunosurveillance immune effector mechanism. This enhancement could be mediated either by increasing the frequency and absolute numbers of effector cells that carry out such function or by enhancement of the cellular mechanisms by which such effector cells mediate their function.
The clinical association of particular importance is between malnutrition and an individual's ability to respond to infectious micro-organisms or their antigenic constituents. Mechanisms by which nutrition affects immunity include reduced phagocytic activity and decreased leukocyte proliferation which, respectively, result in less vigorous microbial elimination and poor clonal expansion of microbe-specific lymphocytes. In addition, cell cycle, transcription regulation, antibody production, cytokine secretion and anti-oxidant protection may also be altered. Thus, the immune problems related to nutritional deficiencies vary from increased opportunistic infections to suboptimal responses following vaccination. In such cases dietary supplementation of micronutrients is likely to enhance immune function.
SUBSTITUTE SHEET (RULE26) wo omsm4 PcrrcAOOroo~o
2 One type of malnutrition is micronuttient malnutrition, which may be defined as the insufficient dietary consumption of nutrients such as vitamin A, zinc, iron and iodine.
It is a significant problem affecting more than 2 billion people worldwide, particularly women and children living in poverty. Iron deficiency is the most common nutritional problem in the world, affecting two thirds of children in most developing nations.
The consequences of iron deficiency anemia are very serious. Anemia resulting from iron deficiency in young children has become very common since the level of bioavailable iron in a typical infant's diet is low while their rapid growth requires a much higher level of iron. The consequences of iron deficiency anemia (IDA) are very serious as it is associated with impaired cognitive and psychomotor development, reduced growth and decreased resistance to infection. Recent demonstration that these negative effects seem not to be reversible, at least until school entry, has significant public health implications. In January 1995, the WHO/LJNICEF Joint Committee on Health Policy decided that iron supplement programs for the prevention of iron deficiency anemia should include infants and children from six months to Five years of age and all low birth-weight infants from three to 12 months.
Vitamin A and its derivatives are important, not only for normal functioning of the eye, but also for normal differentiation of several tissues. Vitamin A is also an essential micronutrient needed in small amounts for normal functioning of the visual system, growth and development, maintenance of epithelial cell inteb ty, immune function, and reproduction. In the vitamin A deficient state, the human is unable to raise an adequate antibody response to bacteria and to maintain the activity and number of killer cells. There is documentation, for example, that mucosal immune response to cholera toxin is impaired. Vitamin A also plays a role in the production of cell glyeoprotein and in the regulation of cell division in the intestine which has a bearing on intestinal epithelial renewal during and after acute enteric infections. An association between vitamin A deficiency and increased diatrttea morbidity has been reported. Vitamin A supplementation has been shown to decrease the mortality from SUBSTITUTE SHEET (RULE26)
It is a significant problem affecting more than 2 billion people worldwide, particularly women and children living in poverty. Iron deficiency is the most common nutritional problem in the world, affecting two thirds of children in most developing nations.
The consequences of iron deficiency anemia are very serious. Anemia resulting from iron deficiency in young children has become very common since the level of bioavailable iron in a typical infant's diet is low while their rapid growth requires a much higher level of iron. The consequences of iron deficiency anemia (IDA) are very serious as it is associated with impaired cognitive and psychomotor development, reduced growth and decreased resistance to infection. Recent demonstration that these negative effects seem not to be reversible, at least until school entry, has significant public health implications. In January 1995, the WHO/LJNICEF Joint Committee on Health Policy decided that iron supplement programs for the prevention of iron deficiency anemia should include infants and children from six months to Five years of age and all low birth-weight infants from three to 12 months.
Vitamin A and its derivatives are important, not only for normal functioning of the eye, but also for normal differentiation of several tissues. Vitamin A is also an essential micronutrient needed in small amounts for normal functioning of the visual system, growth and development, maintenance of epithelial cell inteb ty, immune function, and reproduction. In the vitamin A deficient state, the human is unable to raise an adequate antibody response to bacteria and to maintain the activity and number of killer cells. There is documentation, for example, that mucosal immune response to cholera toxin is impaired. Vitamin A also plays a role in the production of cell glyeoprotein and in the regulation of cell division in the intestine which has a bearing on intestinal epithelial renewal during and after acute enteric infections. An association between vitamin A deficiency and increased diatrttea morbidity has been reported. Vitamin A supplementation has been shown to decrease the mortality from SUBSTITUTE SHEET (RULE26)
3 diarrhea and measles. Since the 'defining' studies of Findlay and Mackenzie in the early 1920's, several reports have suggested an interaction between vitamin A
and iron metabolism. These early studies demonstrated a reduction in hematopoietic cells in bone marrow and hemosiderosis in the liver and spleen in vitamin A
deficient subjects. These and later studies also suggested that the lack of vitamin A
may lead to a mild anemia characterized by low serum Fe and elevated level of Fe in storage depots, especially in the liver. An array of epidemiological studies indicated that vitamin A deficiency and anemia often coexist.
Zinc is another nutritionally essential micronutrient for humans. The zinc atom has a unique combination of properties that renders it useful in biologic systems.
Zinc is an essential component of more than 200 enzymes pervading all metabolic pathways.
The role of zinc in such enzymes can be structural and catalytic. Zinc is essential for cell growth and has a fundamental role in gene replication, activation, repression, transcription and translation.
The biologic actions of zinc have an important bearing on various components of the immune system. Zinc deficiency, both acquired and inherited, is associated with lymphoid atrophy, decreased cutaneous delayed hypersensitivity responses, lower thymic hormone activity, a decreased number of antibody-forming cells and impaired T-killer-cell activity. Reduced activity of thymic hormone which is involved in the differentiation of T cells has also been described in zinc deficiency.
Bhan et a1.1 describe the role of Zinc and Vitamin A supplementation for the prevention of diarrhea caused by malnutrition. Sazawal et a1.2 evaluated the effect of daily supplementation with 10 mg of elemental zinc on the incidence and prevalence of acute lower respiratory infection in a double-blind, randomized, controlled trial finding that a dietary zinc supplement resulted in a significant reduction in SUBSTITUTE SHEET (RULE Z6) wo otns~ts >PCr~c~oo~oo~o
and iron metabolism. These early studies demonstrated a reduction in hematopoietic cells in bone marrow and hemosiderosis in the liver and spleen in vitamin A
deficient subjects. These and later studies also suggested that the lack of vitamin A
may lead to a mild anemia characterized by low serum Fe and elevated level of Fe in storage depots, especially in the liver. An array of epidemiological studies indicated that vitamin A deficiency and anemia often coexist.
Zinc is another nutritionally essential micronutrient for humans. The zinc atom has a unique combination of properties that renders it useful in biologic systems.
Zinc is an essential component of more than 200 enzymes pervading all metabolic pathways.
The role of zinc in such enzymes can be structural and catalytic. Zinc is essential for cell growth and has a fundamental role in gene replication, activation, repression, transcription and translation.
The biologic actions of zinc have an important bearing on various components of the immune system. Zinc deficiency, both acquired and inherited, is associated with lymphoid atrophy, decreased cutaneous delayed hypersensitivity responses, lower thymic hormone activity, a decreased number of antibody-forming cells and impaired T-killer-cell activity. Reduced activity of thymic hormone which is involved in the differentiation of T cells has also been described in zinc deficiency.
Bhan et a1.1 describe the role of Zinc and Vitamin A supplementation for the prevention of diarrhea caused by malnutrition. Sazawal et a1.2 evaluated the effect of daily supplementation with 10 mg of elemental zinc on the incidence and prevalence of acute lower respiratory infection in a double-blind, randomized, controlled trial finding that a dietary zinc supplement resulted in a significant reduction in SUBSTITUTE SHEET (RULE Z6) wo otns~ts >PCr~c~oo~oo~o
4 respiratory morbidity in preschool children. Interventions to improve zinc intake may improve the health and survival of children in developing countries.
However, these prior art reference do not disclose combining micronutrients with prebiotics and probiotics in a lipid-based excipient, in order to provide a composition which is readily administrable on addition to food.
Another factor critical to the immune system is the prevention of infection of the gastrointestinal (Gn tract. The GI tract is a dynamic and integrated ecosystem composed of an organized matrix of host cells, a fully functional immune system and numerous microbial habitats normally colonized by a diverse array of commensal bacterial species. Indigenous non-pathogenic (non-harmful) gut bacteria occupying intestinal habitats provide the front lint of mucosal defense against infection. Normal gut bacteria directly prevent intestinal colonization of pathogenic (potentially harmful) organisms by competing more successfully for essential nutrients or for epithelial attachment sites. Through the production of antimicrobial compounds, volatile fatty acids and chemically modified bile acids, indigenous gut bacteria also create a local gut environment that is unfavorable for the growth of most enteric pathogens. Indeed, all animals have, and seemingly require, long-term cooperative associations with commensal bacteria in the GI tract.
During the birth process and rapidly thereafter, microbes from the rnother and surrounding environment colonize the GI tract. Gut bacterial groups then undergo a characteristic succession until a dense, complex, and stable microbiota has developed. Bacterial succession from that time onward, involves microbe-microbe and host-microbe interactions and is dependent on host supplied exogenous and endogenous nutrients. Thus nutritional modulation of the intestinal microbiota critically affects the susceptibility to enteric diseases and likely has long-term effects on immune competence and self-tolerance.
SUBSTITUTE SHEET (RULE Z6) wo oms~m rcmcnooroo~o Collins et a1.3 discuss the role played by probiotics, prebiotics, and synbiotics in maintaining the health of the human large intestine, as well as dietary supplementation with probiotics, prebiotics, and synbiotics. However, this prior art reference does not disclose combining micronutrients with prebiotics and probiotics
However, these prior art reference do not disclose combining micronutrients with prebiotics and probiotics in a lipid-based excipient, in order to provide a composition which is readily administrable on addition to food.
Another factor critical to the immune system is the prevention of infection of the gastrointestinal (Gn tract. The GI tract is a dynamic and integrated ecosystem composed of an organized matrix of host cells, a fully functional immune system and numerous microbial habitats normally colonized by a diverse array of commensal bacterial species. Indigenous non-pathogenic (non-harmful) gut bacteria occupying intestinal habitats provide the front lint of mucosal defense against infection. Normal gut bacteria directly prevent intestinal colonization of pathogenic (potentially harmful) organisms by competing more successfully for essential nutrients or for epithelial attachment sites. Through the production of antimicrobial compounds, volatile fatty acids and chemically modified bile acids, indigenous gut bacteria also create a local gut environment that is unfavorable for the growth of most enteric pathogens. Indeed, all animals have, and seemingly require, long-term cooperative associations with commensal bacteria in the GI tract.
During the birth process and rapidly thereafter, microbes from the rnother and surrounding environment colonize the GI tract. Gut bacterial groups then undergo a characteristic succession until a dense, complex, and stable microbiota has developed. Bacterial succession from that time onward, involves microbe-microbe and host-microbe interactions and is dependent on host supplied exogenous and endogenous nutrients. Thus nutritional modulation of the intestinal microbiota critically affects the susceptibility to enteric diseases and likely has long-term effects on immune competence and self-tolerance.
SUBSTITUTE SHEET (RULE Z6) wo oms~m rcmcnooroo~o Collins et a1.3 discuss the role played by probiotics, prebiotics, and synbiotics in maintaining the health of the human large intestine, as well as dietary supplementation with probiotics, prebiotics, and synbiotics. However, this prior art reference does not disclose combining micronutrients with prebiotics and probiotics
5 in a lipid-based excipient, in order to provide a composition which is readily administrable on addition to food.
Micronutrient malnutrition can be prevented, or at least controlled, by diet diversification, food fortification and nutrient supplementation. However, these solutions cannot readily be implemented in developing countries. For example, the ability of those in developing countries to diversify their diet is dictated not only by the availability of foods with a high nutrient content, but more importantly by the cost of such foods. Micronutrient-fortified foods are, of course, an appropriate, effective means to prevent malnutrition; however, the cost of these foods is prohibitive to most families living in developing countries, or in developed countries, but who cannot afford these foods.
Although, in an ideal world, the prevention of micronutrient deficiency would be through the ingestion of rnicronutrient-containing foods, the majority of infants in developing countries live in families where the cost of nutrient dense foods is prohibitive. Thus, alternate strategies must be found, like the use of micronutrient and prebiotic, probiotic and synbiotic supplements. Unlike in older children and adults, infants cannot swallow tablets or pills. Thus, presently, micronutrients such as iron are given in the form of a solution (syrup or drops) supplements for infants and young children. Iron solutions have significant disadvantages compared to tablets or pills, including shorter half life and a higher cost of shipping. more complicated dispensing directions, a higher likelihood of dosage errors, possible staining of teeth (reversible), poor compliance (the strong metallic taste of iron drastically reduces compliance) and SUBSTITUTE SHEET (RULE26)
Micronutrient malnutrition can be prevented, or at least controlled, by diet diversification, food fortification and nutrient supplementation. However, these solutions cannot readily be implemented in developing countries. For example, the ability of those in developing countries to diversify their diet is dictated not only by the availability of foods with a high nutrient content, but more importantly by the cost of such foods. Micronutrient-fortified foods are, of course, an appropriate, effective means to prevent malnutrition; however, the cost of these foods is prohibitive to most families living in developing countries, or in developed countries, but who cannot afford these foods.
Although, in an ideal world, the prevention of micronutrient deficiency would be through the ingestion of rnicronutrient-containing foods, the majority of infants in developing countries live in families where the cost of nutrient dense foods is prohibitive. Thus, alternate strategies must be found, like the use of micronutrient and prebiotic, probiotic and synbiotic supplements. Unlike in older children and adults, infants cannot swallow tablets or pills. Thus, presently, micronutrients such as iron are given in the form of a solution (syrup or drops) supplements for infants and young children. Iron solutions have significant disadvantages compared to tablets or pills, including shorter half life and a higher cost of shipping. more complicated dispensing directions, a higher likelihood of dosage errors, possible staining of teeth (reversible), poor compliance (the strong metallic taste of iron drastically reduces compliance) and SUBSTITUTE SHEET (RULE26)
6 caregiver burnout (infants object to the drops thus caregivers tend to quickly give up.
Vitamin A is often provided via an intramuscular injection or periodic massive doses.
Intramuscular injections are painful and must be repeated at regular intervals to be effective over the long-term. Periodic dosing can cause temporary vitamin A
toxicity if the dose is very high, but more importantly, periodic dosing is quite expensive since a health care worker administers the dose. There are advantages to provide iow dose micronutrients such as vitamin A on a daily basis, such as the lower cost of delivery, potentially better absorption of low doses repeated frequently than large doses provided infrequently, a more efficient delivery system since the sachet is used in homes by parents without the need for health care workers.
The use of excipients such as waxes and lipids is well known in the art, for example U.S. patent 4,882,167 to Jang, which is incorporated by reference, teaches a hydrophobic carbohydrate polymer and a wax, fatty acid material or neutral lipid for use in a controlled release dosage form. U.S. patent 5,162,057 to Akiyama, which is incorporated by reference, discloses coating agents such as fatty acid esters of polyglycerols, which may optionally include waxes.
A composition containing lipid-coated micronutrients and the use of this composition to coat food products during the manufacturing process is taught in U.S.
patent 3,993,556 to Kovacs, which discloses mixing a micronutrient with a melted fat carrier and then applying the fat carrier/food supplement mixture to the surface of a pre-made food product and cooling the food product below the melting point of the fat. Kovacs also discloses a toasting or heating process by which the layer of food supplement is attached to food products such as breakfast cereals, crackers, cookies, potato chips, and similar snack foods, flour and pasta. Kovacs teaches the addition of the food supplementlfat carrier mixture during the food manufacturing process.
SUBSTITUTE SHEET {RUI,E26) WO 01/1571d PCT/CA00/00990
Vitamin A is often provided via an intramuscular injection or periodic massive doses.
Intramuscular injections are painful and must be repeated at regular intervals to be effective over the long-term. Periodic dosing can cause temporary vitamin A
toxicity if the dose is very high, but more importantly, periodic dosing is quite expensive since a health care worker administers the dose. There are advantages to provide iow dose micronutrients such as vitamin A on a daily basis, such as the lower cost of delivery, potentially better absorption of low doses repeated frequently than large doses provided infrequently, a more efficient delivery system since the sachet is used in homes by parents without the need for health care workers.
The use of excipients such as waxes and lipids is well known in the art, for example U.S. patent 4,882,167 to Jang, which is incorporated by reference, teaches a hydrophobic carbohydrate polymer and a wax, fatty acid material or neutral lipid for use in a controlled release dosage form. U.S. patent 5,162,057 to Akiyama, which is incorporated by reference, discloses coating agents such as fatty acid esters of polyglycerols, which may optionally include waxes.
A composition containing lipid-coated micronutrients and the use of this composition to coat food products during the manufacturing process is taught in U.S.
patent 3,993,556 to Kovacs, which discloses mixing a micronutrient with a melted fat carrier and then applying the fat carrier/food supplement mixture to the surface of a pre-made food product and cooling the food product below the melting point of the fat. Kovacs also discloses a toasting or heating process by which the layer of food supplement is attached to food products such as breakfast cereals, crackers, cookies, potato chips, and similar snack foods, flour and pasta. Kovacs teaches the addition of the food supplementlfat carrier mixture during the food manufacturing process.
SUBSTITUTE SHEET {RUI,E26) WO 01/1571d PCT/CA00/00990
7 However. such a composition cannot be readily administered to food by the eventual consumer.
In my Canadian patent application 2,230,801, which is incorporated by reference, a composition containing microencapsulated iron granules in combination with a lipid s based excipient is described. The composition may be added to food by the consumer, and can be used with liquid foods. However, this application does not disclose supplementation with micronutrients other than iron, nor does it disclose the use of prebiotics, probiatics or synbiotics to stimulate the non-pathogenic bacterial populations of the gastrointestinal tract.
Accordingly, there is a need for a composition which combines micronutrient supplementation with supplements for stimulation of the non-pathogenic bacterial populations in the GI tract, in order to improve general immunity. Such a composition is needed in an inexpensive form which can be easily added to food and is suitable for use with infants or young children.
Summary of the Invention It is an object of the present invention to provide a composition for enhancement of general immunity in a mammal, which combines micronutrient supplements, prebiotics, probiotics, or synbiotics. The present composition advantageously ?0 provides the micronutrients in combination with one of a prebiotic, probiotic. and symbiotic in an inexpensive form which is readily administrable on addition to food. The micronutrients may be micro-encapsulated.
It is another object of the present invention to provide a composition containing micronutrients in combination with prebiotics, probiotics or synbiotics, which may be sprinkled directly on to foods, which is inexpensive to manufacture and has a long shelf life.
SUBSTITUTE SHEET (RULE26) WO 01/15714 PCT/CAOO/t10990
In my Canadian patent application 2,230,801, which is incorporated by reference, a composition containing microencapsulated iron granules in combination with a lipid s based excipient is described. The composition may be added to food by the consumer, and can be used with liquid foods. However, this application does not disclose supplementation with micronutrients other than iron, nor does it disclose the use of prebiotics, probiatics or synbiotics to stimulate the non-pathogenic bacterial populations of the gastrointestinal tract.
Accordingly, there is a need for a composition which combines micronutrient supplementation with supplements for stimulation of the non-pathogenic bacterial populations in the GI tract, in order to improve general immunity. Such a composition is needed in an inexpensive form which can be easily added to food and is suitable for use with infants or young children.
Summary of the Invention It is an object of the present invention to provide a composition for enhancement of general immunity in a mammal, which combines micronutrient supplements, prebiotics, probiotics, or synbiotics. The present composition advantageously ?0 provides the micronutrients in combination with one of a prebiotic, probiotic. and symbiotic in an inexpensive form which is readily administrable on addition to food. The micronutrients may be micro-encapsulated.
It is another object of the present invention to provide a composition containing micronutrients in combination with prebiotics, probiotics or synbiotics, which may be sprinkled directly on to foods, which is inexpensive to manufacture and has a long shelf life.
SUBSTITUTE SHEET (RULE26) WO 01/15714 PCT/CAOO/t10990
8 It is a further object of the present invention to provide a composition with numerous advantages over old methods of micronutrient and prebiotic or probiotic supplementation. When added to food, the composition does not change the colour or texture of the food. The taste of infant cereals is not affected, at least from an adult perspecti ve.
In a preferred embodiment, the composition is provided in single-dose sachets which ace simple to use, reduce wastage and reduce the likelihood of an accidental overdose from the ingestion of too much micronutrient.
According to an aspect of the present invention, there is provided a composition useful for enhancing general immunity comprising: at least one micronutrient in a bio-available form; one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipicnt, and a carbohydrate-based excipient.
According to another aspect of the invention, a use of the above composition is provided, wherein a therapeutically effective amount of the composition is added to food to be administered to a mammal.
According to a further aspect of the invention, there is provided a process for producing a composition useful for enhancing the general immunity of a mammal which consists essentially of the step of combining a micronutrient in a bio-available from with one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic and a pharmaceutically acceptable excipient selected from a group of a lipid-based excipient and a carbohydrate-based excipient.
According to yet another aspect of the invention there is provided a method for SUBSTITUTE SHEET (RULE Z6) wo ains~ia Pc~ricAOOroo~o
In a preferred embodiment, the composition is provided in single-dose sachets which ace simple to use, reduce wastage and reduce the likelihood of an accidental overdose from the ingestion of too much micronutrient.
According to an aspect of the present invention, there is provided a composition useful for enhancing general immunity comprising: at least one micronutrient in a bio-available form; one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipicnt, and a carbohydrate-based excipient.
According to another aspect of the invention, a use of the above composition is provided, wherein a therapeutically effective amount of the composition is added to food to be administered to a mammal.
According to a further aspect of the invention, there is provided a process for producing a composition useful for enhancing the general immunity of a mammal which consists essentially of the step of combining a micronutrient in a bio-available from with one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic and a pharmaceutically acceptable excipient selected from a group of a lipid-based excipient and a carbohydrate-based excipient.
According to yet another aspect of the invention there is provided a method for SUBSTITUTE SHEET (RULE Z6) wo ains~ia Pc~ricAOOroo~o
9 enhancing the general immunity of a mammal comprising the steps of removing a composition comprising micro-encapsulated micronutrient granules, a substance selected from the group of a prebiotic, probiotic or symbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient, from packaging material; adding a therapeutically effective amount of said composition to a food; and administering the food to said mammal.
According to a further aspect of the invention there is provided a method of treating iron deficiency anemia in children comprising administering a composition comprising microencapsulated iron in a bioavailable form; one or more compounds selected from the group of a prebiotic, probiotic, and symbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient.
IS
According to a further aspect of the present invention, there is provided an article of manufacture including packaging material and a pharmaceutical composition contained within said packaging material which is effective to enhance general immunity. The composition comprises one or more micronutrients, one or more 30 compounds selected from the group of a prebiotic, probiotic, and symbiotic, and pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient.
Other objects, features and advantages of the present invention will become 25 apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention arc given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will SUBSTITUTE SHEET (RULE26) become apparent to those skilled in the art from this detailed description.
Brief Description of the Drawings FIGURE 1 is a bar graph illustrating the effect of various iron-containing 5 compositions on hemoglobin response in rats.
Detailed Description of the Invention The term "enhance genera! immunity" or "enhancing general immunity" as it is used herein refers to the development of an effective immune system through enhancement
According to a further aspect of the invention there is provided a method of treating iron deficiency anemia in children comprising administering a composition comprising microencapsulated iron in a bioavailable form; one or more compounds selected from the group of a prebiotic, probiotic, and symbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient.
IS
According to a further aspect of the present invention, there is provided an article of manufacture including packaging material and a pharmaceutical composition contained within said packaging material which is effective to enhance general immunity. The composition comprises one or more micronutrients, one or more 30 compounds selected from the group of a prebiotic, probiotic, and symbiotic, and pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient.
Other objects, features and advantages of the present invention will become 25 apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention arc given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will SUBSTITUTE SHEET (RULE26) become apparent to those skilled in the art from this detailed description.
Brief Description of the Drawings FIGURE 1 is a bar graph illustrating the effect of various iron-containing 5 compositions on hemoglobin response in rats.
Detailed Description of the Invention The term "enhance genera! immunity" or "enhancing general immunity" as it is used herein refers to the development of an effective immune system through enhancement
10 of the natural immunosurveillance immune effector mechanism. The enhancement could be mediated by either increasing the frequency and absolute number of effector cells that carry out such function or by enhancement of the cellular mechanisms by which such effector cells mediate their function. In addition, the term "enhance general immunity" or "enhancing general immunity" as it is used herein also refers to 1 S the growth of non-pathogenic bacteria in the gut in order to provide the front line of mucosal defense against infection, prevent intestinal colonization of pathogenic organisms, and create a local gut environment that is unfavorable for the growth of most enteric pathogens.
The term "micronutrient" as used herein refers to essential dietary nutrients needed by humans in small amounts. Their absence over varying pet;ods of time will result in clinical deficiency syndromes. The preferred micronutrients for the present invention are iron, zinc, iodine, vitamin A, and vitamin C (ascorbic acid).
The term "prebiotic" as used herein refers to a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth, activity or both of one or a limited number of bacterial species already resident in the colon4, Preferably, SUBSTITUTE SHEET (RULE Z6) wo ovts~i4 pcric~ooroo~sro
The term "micronutrient" as used herein refers to essential dietary nutrients needed by humans in small amounts. Their absence over varying pet;ods of time will result in clinical deficiency syndromes. The preferred micronutrients for the present invention are iron, zinc, iodine, vitamin A, and vitamin C (ascorbic acid).
The term "prebiotic" as used herein refers to a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth, activity or both of one or a limited number of bacterial species already resident in the colon4, Preferably, SUBSTITUTE SHEET (RULE Z6) wo ovts~i4 pcric~ooroo~sro
11 a prebiotic should also be:
(l) neither hydrolyzed by nor absorbed in the upper part of the intestinal tract;
(ii) a selective substrate for one or a limited number of potentially beneficial commensal bacteria in the colon, thus stimulating the bacteria to grow, become metabolically activated, or both; and (iii) able, as a consequence, to alter the colon microflora toward a more healthy composition.
Most prebiotics are directed toward the growth of lactic acid-producing organisms because of the positive effect these organisms have on the GI tract. Examples of prebiotics include but are not limited to fructootigosaccharide (FOS) (e. g.
oligofructose and neosugar), inulin, glucooligosaccharide (GOS), lactulose, and lactitol.
The preferred prebiotic according to the present invention is FOS. FOS is derived from the chicory plant and is commercially available. Consumption of FOS has been shown to result in numerical predominance of bifidobacteria in feces. The following health advantages have been shown to be associated with bifidobateria in the adult and infant human gut3:
(l) inhibition of pathogen growth;
(iv) immunomodulatory activity;
(v) restoration of gut flora after antibiotic therapy;
(vi) production of digestive enzymes;
(vii) positive effects on antibiotic-associated diarrhea; and SUBSTITUTE SHEET (RULE26) WO 01!15714 PCTlCA00/00990
(l) neither hydrolyzed by nor absorbed in the upper part of the intestinal tract;
(ii) a selective substrate for one or a limited number of potentially beneficial commensal bacteria in the colon, thus stimulating the bacteria to grow, become metabolically activated, or both; and (iii) able, as a consequence, to alter the colon microflora toward a more healthy composition.
Most prebiotics are directed toward the growth of lactic acid-producing organisms because of the positive effect these organisms have on the GI tract. Examples of prebiotics include but are not limited to fructootigosaccharide (FOS) (e. g.
oligofructose and neosugar), inulin, glucooligosaccharide (GOS), lactulose, and lactitol.
The preferred prebiotic according to the present invention is FOS. FOS is derived from the chicory plant and is commercially available. Consumption of FOS has been shown to result in numerical predominance of bifidobacteria in feces. The following health advantages have been shown to be associated with bifidobateria in the adult and infant human gut3:
(l) inhibition of pathogen growth;
(iv) immunomodulatory activity;
(v) restoration of gut flora after antibiotic therapy;
(vi) production of digestive enzymes;
(vii) positive effects on antibiotic-associated diarrhea; and SUBSTITUTE SHEET (RULE26) WO 01!15714 PCTlCA00/00990
12 (viii) repression of rotaviruses.
The term "probiotic" as used herein refers to a live microbial food supplement that beneficially affects the host animal by improving its intestinal microbial balance.
Preferably, the present composition includes a probiotic which:
(i) exerts a beneficial effect on the host;
(ix) is nonpathogenic and non toxic;
(x) contains a large number of viable cells;
(xi) is capable of surviving and functioning in the gut; and LO (xii) remains viable during storage and use.
Health advantages associated with probiotic intake include: 6, ~
(xiii) alleviation of symptoms of lactose malabsorption;
(xiv) increased natural resistance to infectious diseases of the intestinal tract;
(xv) improved digestion; and (xvi) stimulation of GI immunity.
Examples of probiotics include but are not limited to Lactobacilli (L.
acidophus. L.
casei. L. del6rueckii subsp. bulgaricus, L. reuteri, L. brevis, L.
cellobiosus. L.
curvatus, L. fermentum, L. planatarum). Gram-positive cocci (Lactocvccus lactis subsp. thernzophilus, Enterrococcus faecium, S. diaacetylactis, S.
intermedius), Bifidobacteria (B. bifdiunt, B. adolescentis, B. animalis, B. infantis, B.
longum, B.
thermophilum) SUBSTITUTE SHEET (RULE26) WO 01/15714 PCT/CA00lOQ990
The term "probiotic" as used herein refers to a live microbial food supplement that beneficially affects the host animal by improving its intestinal microbial balance.
Preferably, the present composition includes a probiotic which:
(i) exerts a beneficial effect on the host;
(ix) is nonpathogenic and non toxic;
(x) contains a large number of viable cells;
(xi) is capable of surviving and functioning in the gut; and LO (xii) remains viable during storage and use.
Health advantages associated with probiotic intake include: 6, ~
(xiii) alleviation of symptoms of lactose malabsorption;
(xiv) increased natural resistance to infectious diseases of the intestinal tract;
(xv) improved digestion; and (xvi) stimulation of GI immunity.
Examples of probiotics include but are not limited to Lactobacilli (L.
acidophus. L.
casei. L. del6rueckii subsp. bulgaricus, L. reuteri, L. brevis, L.
cellobiosus. L.
curvatus, L. fermentum, L. planatarum). Gram-positive cocci (Lactocvccus lactis subsp. thernzophilus, Enterrococcus faecium, S. diaacetylactis, S.
intermedius), Bifidobacteria (B. bifdiunt, B. adolescentis, B. animalis, B. infantis, B.
longum, B.
thermophilum) SUBSTITUTE SHEET (RULE26) WO 01/15714 PCT/CA00lOQ990
13 The terrn "synbiotic" as used herein refers to the combination use of pre-and probiotics4. Examples of synbiotics include but are not limited to Bifidobacteria +FOS, Lactobacilli + lactitol, and Bifidobacteria + GOS.
The term "lipid-based", as it is used herein with respect to the excipient, is meant to refer to excipients which are lipids, or which comprise a lipid component.
Lipid-based excipients will combine with the mieroencapsulatcd micronuttient granules of the present composition in a chemically stable manner in which no adverse interaction occurs such as undesirable aesthetic changes or undesirable changes to the taste of the product. Moreover, lipid-based excipients conveniently allow combination of the composition with foods, the means by which it is administered.
The term "carbohydrate-based" as it is used herein with respect to the excipient, is meant to refer to excipients which are carbohydrates, or which comprise a carbohydrate component. Examples of suitable carbohydrate-based excipients are dextrin, corn syrup solids or glucose polymers.
Preferably, the micronutr-ient is microcncapsulated. In a preferred embodiment, one of the micronutrients included in the composition of the present invention, is iron in the form of microencapsulated iron granules. Microencapsulation of iron protects the iron from the food to which it is added. Iron is a potent oxidizing agent. When a soluble form of iron comes in contact with food, it can change the colour, taste and smell of the food. To prevent this from occurring, the iron is encapsulated with a thin soy-lipid coating. The microencapsulated iron granules of the present composition may comprise any bioavailable solid form of iron including iron salts such as ferrous sulphate, ferrous fumarate, ferrous succinate, ferrous gluconate, ferric pyrophosphate, ferric sacchxrate, ferric orthophosphate or any other compound capable of providing SUBSTITUTE SHEET (RULE26)
The term "lipid-based", as it is used herein with respect to the excipient, is meant to refer to excipients which are lipids, or which comprise a lipid component.
Lipid-based excipients will combine with the mieroencapsulatcd micronuttient granules of the present composition in a chemically stable manner in which no adverse interaction occurs such as undesirable aesthetic changes or undesirable changes to the taste of the product. Moreover, lipid-based excipients conveniently allow combination of the composition with foods, the means by which it is administered.
The term "carbohydrate-based" as it is used herein with respect to the excipient, is meant to refer to excipients which are carbohydrates, or which comprise a carbohydrate component. Examples of suitable carbohydrate-based excipients are dextrin, corn syrup solids or glucose polymers.
Preferably, the micronutr-ient is microcncapsulated. In a preferred embodiment, one of the micronutrients included in the composition of the present invention, is iron in the form of microencapsulated iron granules. Microencapsulation of iron protects the iron from the food to which it is added. Iron is a potent oxidizing agent. When a soluble form of iron comes in contact with food, it can change the colour, taste and smell of the food. To prevent this from occurring, the iron is encapsulated with a thin soy-lipid coating. The microencapsulated iron granules of the present composition may comprise any bioavailable solid form of iron including iron salts such as ferrous sulphate, ferrous fumarate, ferrous succinate, ferrous gluconate, ferric pyrophosphate, ferric sacchxrate, ferric orthophosphate or any other compound capable of providing SUBSTITUTE SHEET (RULE26)
14 PCT/CA00N0990 iron with an appropriate bioavailability. Bioavailability can be deletmined using the standard "hemoglobin-repletion" method described in detail by Fritz et a1.8 This method generally involves feeding anemic rats with a test iron compound and comparing their iron uptake with the iron uptake of anemic rats fed a reference compound determined to have a relative iron bioavai (ability of 100%.
In a most preferred embodiment, ferrous fumarate is combined with FeNaEDTA
(Iron sodium fiDTA). This combination of two iron sources increases the bioavailablc iron. Cereals such as maize arc high in phytate content, which decreases the absorption of ;Iron. The addition of FeNaEDTA aids in the absorption of the natural iron in the cereal as well as any iron exogenously added to the cereal. The NaEDTA binds the phytate, thus allowing the iron to be absorbed from the proximal small intestine (the duodenum).
!5 The selected iron compound is formed into granules using techniques and machinery well-known to those of skill in the art. For use in the present composition, granules preferably have a diameter of no more than about 850 microns. Granules of this size range can be obtained, for example, using a U.
S. No.
sieve. The granulated iron compound is provided as a fine free flowing powder.
Once formed into granules of a desired size, the iron compound may be coated or encapsulated with an inert substance that will not interfere with the uptake of the iron compound. The coating functions to sustain the release of the iron, effectively masking the characteristic unpleasant taste of the iron compound, preventing 35 discoloration of the foods to which it is added, thereby providing a form of iron that can readily be added to foods. The coating also prevents the undesirable interaction between nutrients in the foods to which it is added as well as additional nutrients that may be added to the composition itself. The inert coating may be selected from SUBSTITUTE SHEET (RULE26) wo otns~ta Pcrrcnooroo~o is a number of suitable substances including, but not limited to, mono-or diglycerides, ethyl cellulose, hydrogenated soybean oil, acacia gum and mixtures thereof.
Alternatively, iron which is supplied in a rnicroencapsulated form may be used, for example DescoteT"' ferrous fumarate.
The encapsulated granulated iron compound is admixed with a pharmaceutically acceptable lipid-based or carbohydrate-based exeipient. The term "pharmaceutically acceptable" refers to an excipient acceptable for use in the pharmaceutical and veterinary arts, which is not toxic or otherwise unacceptable. Examples of suitable ZO lipid-based excipients include mono-, dl- and tri-glycerides, especially naturally extracted unsaturated edible oils in hydrogenated form (such as vegetable oil, castor oil, cottonseed oil, corn oil, canola oil, rapeseed oil, peanut oil, sesame seed oil, coconut oil and mixtures thereof). Examples of suitable carbohydrate-based excipients include dextran. A most preferred excipient contains corn syrup solids, hydrogenated vegetable oil and/or hydrogenated coconut oil, sodium caseinate, potassium phosphate di-basic, sodium phosphate di-basic, mono and diglycerides.
acetyfated tartaric acid esters of monoglycerides, artificial colour, and natural and artificial flavour.
Further, the absorption of iron is known to be enhanced in the presence of reducing compounds. Examples of reducing compounds are compounds containing suifhydryl groups such as the amino acids, lysine and histidine. The absorption of iron is also enhanced in the presence of meat. Accordingly, the present composition can advantageously be consumed with meat. Alternatively, the present composition may additionally contain desiccated meat particles to provide enhanced iron absorption and to provide protein content that would be particularly desirable for administration to populations in which protein consumption is low, such as populations in developing countries.
SUBSTITUTE SHEET (RULE26) WO 01/15714 PCTlCA00/00990 Preferably, the present composition is supplemented with additional micronutrients.
Such additional micronutrients may function to enhance the immune system, as well as to enhance the absorption of iron on administration. In a preferred embodiment of the present invention, the composition additionally comprises ascorbic acid (vitamin C), preferably in an amount ranging from about 40-50 mg per 15 mg of elemental iron. The ascorbic acid enhances the absorption of the iron into the bloodstream, providing a more effective composition. Alternatively, or additionally, the present composition may be supplemented with other micronuttients, particularly those micronutrients which are typically absent from the diet or present in insufficient quantities. Examples of micronutrients that may be added to the composition include vitamin A, zinc and iodine, provided in appropriate bioavailable form. In this regard, vitamin A may be added to the present composition in the form of retinyl palmitate or retinol acetate, zinc may be added in the form of zinc sulfate or zinc gluconate, while iodine may be added in the form of potassium iodide. The iodine is preferably coated with dextran, which helps to prevent oxidation.
It will be appreciated that suitable amounts of additional micronutrients will vary with the micronutrient in question. Far example, amounts of about 0.35-0.45 mg of retinyl palmitate per 15 mg of elemental iron, about 5-IO mg of elemental zinc per 15 mg of elemental iron and about 0.25-0.5 mg of iodine per 15 mg of elemental iron may appropriately be added to the present composition.
Davidsson9 recently demonstrated geometric mean [5'Fe] ferrous fumarate bioavailability from cereal of 4.1% (range 1.7-14.7%) and 1.3% (range 0.7-2.7%) from [s'Fe]
ferric pyrophosphate in non-anemic infants. In vitro bioavailability data from our laboratory suggests a range of bioavailability of encapsulated ferrous fumarate of 1.5-3%. If the iron requirement (the amount of 'absorbed' iron) far the non-anemic infant is around 1 mglday SUBSTITUTE SHEET (RULE26) wo otns~t4 pcricnooroo~o and I.5 mg/day for the anemic infant, then the range of doses of oral iron needed to achieve the iron requirement would be as indicated in the table below:
Table 1: Dosage range of oral iron for infants S
ose of oral uirement at iron to achieve ..
estimated iron re Iron Re uirementI.5% abso 3.0% abso lion .5% abso lion tion 1 1.0 m da 66.7 m * 33.3 m 22.2 m - - -_ .
.
_ 1.5 mglday~ _ 50 mg 33.3 mg -L 00 rng * calculated as 1.5% of an unknown dose = i mg; thus 1.5% x 66.7 = 1 mg LO To the micronutrient composition is added a prebiotic, probiotic or synbiotic.
Although traditional freeze-dried probiotics can be used, live probiotics are preferred.
To protect the probiotic from degrading, the probiotic is preferably encapsulated with wax such as beeswax, carnauba wax, spermaceti, lecithin, paraffin and microcrystalline wax, a carbohydrate such as dextran or most preferably a thin
In a most preferred embodiment, ferrous fumarate is combined with FeNaEDTA
(Iron sodium fiDTA). This combination of two iron sources increases the bioavailablc iron. Cereals such as maize arc high in phytate content, which decreases the absorption of ;Iron. The addition of FeNaEDTA aids in the absorption of the natural iron in the cereal as well as any iron exogenously added to the cereal. The NaEDTA binds the phytate, thus allowing the iron to be absorbed from the proximal small intestine (the duodenum).
!5 The selected iron compound is formed into granules using techniques and machinery well-known to those of skill in the art. For use in the present composition, granules preferably have a diameter of no more than about 850 microns. Granules of this size range can be obtained, for example, using a U.
S. No.
sieve. The granulated iron compound is provided as a fine free flowing powder.
Once formed into granules of a desired size, the iron compound may be coated or encapsulated with an inert substance that will not interfere with the uptake of the iron compound. The coating functions to sustain the release of the iron, effectively masking the characteristic unpleasant taste of the iron compound, preventing 35 discoloration of the foods to which it is added, thereby providing a form of iron that can readily be added to foods. The coating also prevents the undesirable interaction between nutrients in the foods to which it is added as well as additional nutrients that may be added to the composition itself. The inert coating may be selected from SUBSTITUTE SHEET (RULE26) wo otns~ta Pcrrcnooroo~o is a number of suitable substances including, but not limited to, mono-or diglycerides, ethyl cellulose, hydrogenated soybean oil, acacia gum and mixtures thereof.
Alternatively, iron which is supplied in a rnicroencapsulated form may be used, for example DescoteT"' ferrous fumarate.
The encapsulated granulated iron compound is admixed with a pharmaceutically acceptable lipid-based or carbohydrate-based exeipient. The term "pharmaceutically acceptable" refers to an excipient acceptable for use in the pharmaceutical and veterinary arts, which is not toxic or otherwise unacceptable. Examples of suitable ZO lipid-based excipients include mono-, dl- and tri-glycerides, especially naturally extracted unsaturated edible oils in hydrogenated form (such as vegetable oil, castor oil, cottonseed oil, corn oil, canola oil, rapeseed oil, peanut oil, sesame seed oil, coconut oil and mixtures thereof). Examples of suitable carbohydrate-based excipients include dextran. A most preferred excipient contains corn syrup solids, hydrogenated vegetable oil and/or hydrogenated coconut oil, sodium caseinate, potassium phosphate di-basic, sodium phosphate di-basic, mono and diglycerides.
acetyfated tartaric acid esters of monoglycerides, artificial colour, and natural and artificial flavour.
Further, the absorption of iron is known to be enhanced in the presence of reducing compounds. Examples of reducing compounds are compounds containing suifhydryl groups such as the amino acids, lysine and histidine. The absorption of iron is also enhanced in the presence of meat. Accordingly, the present composition can advantageously be consumed with meat. Alternatively, the present composition may additionally contain desiccated meat particles to provide enhanced iron absorption and to provide protein content that would be particularly desirable for administration to populations in which protein consumption is low, such as populations in developing countries.
SUBSTITUTE SHEET (RULE26) WO 01/15714 PCTlCA00/00990 Preferably, the present composition is supplemented with additional micronutrients.
Such additional micronutrients may function to enhance the immune system, as well as to enhance the absorption of iron on administration. In a preferred embodiment of the present invention, the composition additionally comprises ascorbic acid (vitamin C), preferably in an amount ranging from about 40-50 mg per 15 mg of elemental iron. The ascorbic acid enhances the absorption of the iron into the bloodstream, providing a more effective composition. Alternatively, or additionally, the present composition may be supplemented with other micronuttients, particularly those micronutrients which are typically absent from the diet or present in insufficient quantities. Examples of micronutrients that may be added to the composition include vitamin A, zinc and iodine, provided in appropriate bioavailable form. In this regard, vitamin A may be added to the present composition in the form of retinyl palmitate or retinol acetate, zinc may be added in the form of zinc sulfate or zinc gluconate, while iodine may be added in the form of potassium iodide. The iodine is preferably coated with dextran, which helps to prevent oxidation.
It will be appreciated that suitable amounts of additional micronutrients will vary with the micronutrient in question. Far example, amounts of about 0.35-0.45 mg of retinyl palmitate per 15 mg of elemental iron, about 5-IO mg of elemental zinc per 15 mg of elemental iron and about 0.25-0.5 mg of iodine per 15 mg of elemental iron may appropriately be added to the present composition.
Davidsson9 recently demonstrated geometric mean [5'Fe] ferrous fumarate bioavailability from cereal of 4.1% (range 1.7-14.7%) and 1.3% (range 0.7-2.7%) from [s'Fe]
ferric pyrophosphate in non-anemic infants. In vitro bioavailability data from our laboratory suggests a range of bioavailability of encapsulated ferrous fumarate of 1.5-3%. If the iron requirement (the amount of 'absorbed' iron) far the non-anemic infant is around 1 mglday SUBSTITUTE SHEET (RULE26) wo otns~t4 pcricnooroo~o and I.5 mg/day for the anemic infant, then the range of doses of oral iron needed to achieve the iron requirement would be as indicated in the table below:
Table 1: Dosage range of oral iron for infants S
ose of oral uirement at iron to achieve ..
estimated iron re Iron Re uirementI.5% abso 3.0% abso lion .5% abso lion tion 1 1.0 m da 66.7 m * 33.3 m 22.2 m - - -_ .
.
_ 1.5 mglday~ _ 50 mg 33.3 mg -L 00 rng * calculated as 1.5% of an unknown dose = i mg; thus 1.5% x 66.7 = 1 mg LO To the micronutrient composition is added a prebiotic, probiotic or synbiotic.
Although traditional freeze-dried probiotics can be used, live probiotics are preferred.
To protect the probiotic from degrading, the probiotic is preferably encapsulated with wax such as beeswax, carnauba wax, spermaceti, lecithin, paraffin and microcrystalline wax, a carbohydrate such as dextran or most preferably a thin
15 vegetable oil coating. Preferably, a microencapsulated form of probiotic that is heat stable even at high environmental temperatures, such as ProbiocapT"" is used.
ProbiocapT"" is encapsulated by coating in a matrix of food-grade vegetable fatty acids. In the past, probiotics had to be kept refrigerated in order to maintain the viability of the bacteria culture. Traditional freeze-dried probivtic bacteria are 20 sensitive to high moisture, extreme temperatures and other physical and chemical stresses. This sensitivity limits their use in many applications. Their viability also decreases during digestion due to the extreme gastric acidity which has long been a concern. Probiotic applications, including the provision of probiotics in non-refrigerated sachets, was limited due to elevated temperatures and the presence of 25 oxygen and moisture that would adversely affect survival rates.
SUBSTITUTE SHEET (RULE Z6) wo ovisma Pcric~ooroo~o 1g It will be appreciated that there is no restriction on the foods or beverages to which the present composition can be added. Since the present composition is particularly beneficial for use in the prevention of anemia in infants and young children, the composition will typically be added to foods and beverages generally consumed by infants and young children. )rxampies of such foods include pureed or semi-solid foods, for example cereals, gtvels, porridges, purees of fruit, vegetables, meat or mixtures thereof, as well as milk-based products including, but not strictly limited to, milk, powdered milk, infant formula, puddings, yogurt, creamed cheese, cottage cheese, and other dairy products which form a part of the diet of infants and young children. The term milk-based products is also meant to include milk substitutes including lactose-free milk and associated products, soy milk and the like.
In a preferred embodiment, a single daily dosage of the composition is packaged, for example in a sachet-type package, comprising about 60 mg of elemental iron in the form of micro-encapsulated granules, prebiotics and probiotics in therapeutically effective amounts, which are known to those skilled in the art , for example, 1 to 2 x 106 colony forming units (CFUs) of probiotics and about 400-mg of excipient. In a particularly preferred embodiment, the package will additionally include ascorbic acid in an amount of about 20-I00 mg, iodine in an amount of 20-100 pg, and vitamin A in an amount of 50-2500 ILI.
A method for enhancement of general immunity in a mammal is also provided. The method involves the steps of adding a therapeutically effective amount of the present composition to a food, and then administering the food to the mammal requiring treatment. The term "therapeutically effective" as it is used with respect to the present composition refers to an amount which is effective to prevent iron deficiency anemia, or at least minimize the occurrence of adverse effects related thereto, while not exceeding an amount which would be toxic or otherwise harmful. In this regard, precise dosage sizes appropriate to prevent anemia can readily be established in SUBSTITUTE SHEET (RULE26) appropriately controlled trials.
The present invention is described in more detail by reference to the following specific examples which are not to be construed as limiting.
S
Example 1 - Preparation of an Iron-containin Composition Encapsulated ferrous fumarate 60% (1 gram delivers 600 mg ferrous fumarate) (Descote~ Ferrous Furnarate 60), having a particle size of no more than about microns in which about 99% of the particles pass through a U. S. No. 20 sieve, was obtained from Particle Dynamic lnc, St. Louis, MO.
Ascorbic acid (3.5 kg; obtained from Basf) was thoroughly mixed in a large aluminum bowl with an excipient (25 kg; obtained from New Dundee Creamery, Division of Ault Foods Limited) containing corn syrup solids, hydrogenated vegetable oil and/or hydrogenated coconut oil, sodium caseinate, potassium phosphate di-basic, sodium phosphate di-basic, mono and diglycerides, acetylated tartaric acid esters of monoglycerides, artificial colour, and natural and artificial flavour.
In a 2-stage fill, 200 mg aliquots of encapsulated ferrous furnarate were added to foil-lined sachet packets followed by the addition of 300 mg of ascorbic acid/excipient mixture. The sachets were appropriately sealed along their open edge.
Optionally, 2.1 kg zinc gluconate is admixed with the ascorbic acid and excipient.
This mixture is then added to ferrous fumarate-containing sachets as set out above.
Example 2 -Relative Bioavailability of Micro-encapsulated Iron SUBSTITUTE SHEET (RULE26) The bioavailability of iron in the composition set out in Example I has been determined using the hemoglobin-repletion test in rats as follows.
5 Male weanling Sprague-Dawley rats housed individually in stainless steel cages were fed a low iron diet and de-ionized distilled water ad lib for 24 days.
The low-iron diet contained no more than about 3 mg of iron per kg of diet. Follomng the 24 day depletion period, approximately 200 ltl of blood was drawn from the tail vein of each rat for hemoglobin analysis. Anemic rats having hemoglobin values 10 between 30 and 60 gJL were used in the study. The rats were housed individually in cafes in a randomized block design. The rats were divided into groups. each group being fed ad libitum a test diet selected from 0, 1U or 20 mg of one of microencapsulated or coated ferrous fumarate (prepared as described in Example 1), microencapsulated or coated ferrous fumarate with zinc, uncoated ferrous fumarate 15 panicles or uncoated ferrous sulphate (a reference compound detertrrined to have a relative bioavailability of 100) per kilogram of diet. The test groups are more specifically set out in the following Table 2:
Table 2: Bioavailability Test Groups # of Ferrous SulfateCoated Coated FerrousFerrous Animals (Fe S047H20)Ferrous Fumarate+ZincFumarate Fulnarate 10 t0 mg Fe/kg 0 0 0 diet 10 20 mg Felkg 0 0 0 SUBSTI?UTE SHEET (RULE26) WO 01115714 PCf/CA00/00990 z1 diet 0 10 mg Fe/kg 0 0 diet 10 0 20 mg Felkg 0 0 diet 10 0 0 0 Fe; 10 mg/kg0 Zn 10 0 0 10 Fe; 10 0 mg/kg Zn 10 0 0 20 Fe; 10 0 mg/kg Zn 10 0 0 0 10 mg Fe/kg diet 10 0 0 0 20 mg Fe/kg diet Total The results, as shown in Figure 1, indicate that hemoglobin response is dependent on the amount of iron in the rat's diet. Moreover, there was no significant difference in 5 the hemoglobin response between rats fed similar amounts of iron as the reference compound (ferrous sulfate) versus rats fed micro-encapsulated ferrous fumarate.
Referring to Fig. 1, the control group represents rats fed a diet containing no iron, the "low iron" diet represents a diet containing 10 mg micro-encapsulated ferrous 10 fumarate/kg of diet, the "high iron control" diet represents a diet containing 20 mg ferrous sulfate/kg of diet and the "high iron" diet represents a diet containing 20 mg SUBSTITUTE SHEET (RULE26) micro-encapsulated ferrous fumarate/kg of diet. There was no change in the hemoglobin of the control after 14 days of feeding, while mean hemoglobin response of the low iron diet group was 18 g/L and the mean hemoglobin response of the high iron control and high iron diet groups was 31 g/L and 33 g/L, respectively.
Example 3 - Preparation of sachets containing 80me iron and 50 mg ascorbic acid For an 80 mg dose of iron, and a SOmg dose of ascorbic acid, the following ingredients were supplied as described in Example 1 and put together and mixed thoroughly. Sachets were filled as a single fill, with 1000 1 gram sachets obtained per kg of raw materials.
Dose I~e~redient ~~Lks Q/sachet 80 mg Descote Ferrous Fumarate 405.60 0.4056 40 mg Ascorbic acid ( 10l0 overage)50.00 0.05 Excipient 544.40 0.5444 TOTAL 1000.00 1.00 Example 4 - Randomised controlled trial of microencapsulated ferrous fumarate sprinkles and ferrous sulphate tops for treatment of anaemia in Ghanaian infants and youne children The effectiveness of the composition of example 3 (referred to as "sprinkles") in treating anaemia in infants and young children has been determined as follows:
In a randomised controlled trial, 837 children (age range 6-24 months:
haemoglobin values 70-99 g/L) were studied. The children were selected from rural villages of SUBSTITUTE SHEET (RULE26) WO 01/15714 PC'f/CA00/00990 Kintampo, Ghana, a malaria-endemic area. One treatment group (n=280) received a daily sachet as described in example 3, containing microencapsulated ferrous fumarate (80 mg elemental iron) plus ascorbic acid; another (n=280) ferrous sulphate drops once daily (40 mg elememal iron); and the control group (n=277) ferrous sulphate drops three times per day (total dose 40 mg elemental iron). Treatment lasted for 2 months. Haemoglobin and serum ferritin values were measured at baseline and 2 months later.
Field workers visited infants at 2-week intervals after the baseline visit, for a total of 5 visits. During the baseline assessment, a written questionnaire was administered to collect demographic, nutritional, and health data for each infant. During the final visit and each of the 2-week visits, a questionnaire about the side effects and compliance over the preceding 7 days (eg, a question about how often the child received drops in the last 7 days) was completed. Data collected about side effects included the 1 S incidence of diarrhea, constipation, and genera) discomfort after ingestion of the coated iron or iron drops. Questions about adherence to treatment included whether the children objected to taking the iron and whether microencapsulated ferrous fumarate changed the colour or consistency of the infants' food. Fieldworkers provided parents with oral educational reinforcement to maximize adherence to the treatment.
Anthropometric measurements, including weight for age, height for age, and weight for height for age, were completed during baseline and final visits. An infant-length board with a sliding foot-board was used for measurement of the child's body length, and a hanging scale graduated in 100-g divisions, for weight measurements. Two fieldworkers completed the measurements in duplicate using standardized techniques.
Capillary blood samples at baseline and final visits were obtained from a finger prick using aseptic techniques, and haemoglobin was measured on the spot with portable SUBSTITUTE SHEET (RULE26) wo ams~t4 rcric~ooioo~o Hemocue photometers (Hemocue Inc, Angelholm, Sweden). Malaria parasite smears were taken (at baseline only), and 500 p.L blood samples were collected and preserved in ice-lined cold boxes. Blood samples were returned to the base station within 6 hours of collection, where the serum was separated by centrifugation (10 minutes at 1300 RPM) before storage at -40°C. Serum ferntin was assayed in duplicate by a commercial enzyme-linked immunosorbent assay (ELISA), using a Spectro Ferritin Kit (Ramco Laboratories, Houston, TX). ~4 Baseline and final ferritin samples from an individual subject were assayed on the same day (in a single batch) on one 96-well microtitre plate to minimise inter-assay variation. An external reference standard (Lyphochek Anaemia Control, Bio-Rad, Anaheim, CA) was assayed in duplicate on each microtitre plate for the ferritin assay.
The blood films were stained and examined for malaria parasites at the end of the study. Children whose blood films indicated a possible malaria infection were treated at home for malaria. Children who were severely anaemic (haemoglobin <70 g/I,) were excluded from the trial and treated.
Those children in the positive control group were given ferrous sulphate drops (5 mg/kg/day of elemental iron, rounded to a total of 40 mg of elemental iron) provided in three equal doses per day. The other two groups received either the ferrous sulphate drops (40 mg) provided daily in a single bolus or microencapsulated ferrous fumarate (80 mg of elemental iron) in the composition of Example 3 packaged in a sachet with ascorbic acid (50 mg), called sprinkles sachets, and added to tire child's meal serving (after it was cooked) once daily.
Children were individually randomised to one of the three treatment groups.
Randomisation was done with sealed opaque envelopes containing group designations, which were generated randomly by computer with Microsoft Access (Microsoft Corporation, Seattle, WA). It was not feasible to blind the field staff or the SUBSTITUTE SHEET (RULE26) WO 01/15114 p~yCApp~ppggp mothers to the group to which the children were assigned. However, the persons responsible for the laboratory and data analyses were blinded to the group designations.
5 Haemoglobin In all groups, there was a significant increase in haemoglobin concentrations from baseline to the end of the study (p<0.001; table 1 ). The change in haemoglobin concentrations (from baseline to final) was similar among treatment groups.
Successful treatment of anaemia (hemoglobin > 100 g/L) occurred in 58°~to in the 10 sprinkles group, in 619'0 of the once-a-day drops group, and in 56°0 of the control group. There was no significant difference between these (p~.51). Ferritin levels increased significantly in each group (p<0.001) although less so in the sprinkles group. Tfie relative risk of remaining anaemic after 2 months of treatment was 1.03 times greater for the sprinkles group (95°lo CI 0.88-1.20, p=0.?5) and 0.92 times 15 lower for once-daily ferrous sulphate group (95% CI 0.79-1.06, p=0.26) than that for the three-times-daily fen;ous sulphate group, but the differences were not significant.
Infants who were positive for malaria were more likely to be anaemic at the end of two months in all groups. The relative risk of remaining anaemic after 2 months of treatment was 1.23 times greater for those with malaria (95Ro CI 1.10-1.37, p~.0006) 20 than those who were malaria-free. The mean haemoglobin values are set out in the following table.
Table 3: Mean haemoglobin (g/L) by treatment group at baseline and after 2 months Treatrncnt group Haemoglobin Sprinkles Drops Drops values (g/L) once daily 3x/day Mean (SD) at Baseline 87 (8) 88 (8) 87 (8) SUBSTITUTE SHEET (RULE26) WO Ol/15714 PCT/CA00/00990 Final 102 (16) 102 (18) 100 (17) Ferritin The geometric mean ferritin values at baseline were similar in all grnups (table 2).
There was a significant increase (around two-fold or more) after 2 months of treatment (p<0.0001); however, the values in both drops gmups were significantly higher than those in the sprinkles group. The variance for ferritin values was quite wide at both baseline and the end of the study as is usual with the wide inter-individual and analytic variance associated with this measure. The ferritin values are set out in the following table.
Table 4: Geometric mcan ferritin values (ltg/L) by treatment group at baseline and after 2 months of intervention Treatment group Fenritin Sprinkles Drops Drops values (pg/i,) once daily 3x/day Baseline 42.9 (99.4) 34.8 (74.8) 45.5 (83.5) Final 81.1 (I40.9j 102.1 (l13 ~) 111.0 (132.1) IS Data are geometric means (SD): analysis was done with log-transformed values since fetritin values are not normally distributed. Mean ferntin increased significantly from baseline to the final visit in all treatment groups (p<0.001). Mean ferritin value at final sampling was significantly lower (pt0.05) from both drops groups. Normal range for ferritin is 12 - 80~tglL for infants 6 to 24 months of age (23) Anthropometric measurements At baseline all infants had similar weight for age z-scores (mean [SD] -1.48 [1.10]), height for age (-1.36 [1.12]) and weight for height (-0.74 [0.94]). No effect of SUBSTITUTE SHEET (RULE26) treatment was found for weight for age and weight for height for age. There was a significant decrease in height-for-age z-scores in all three groups from baseline to the final measurements (mean [SDj change -0.16 [0.79], p<0.001). The anthropometric measurements are set out in the following table.
Table 5: Anthropometric measurements for each treatment group at baseline and after 2 months of intervention Treatment groups Anthropometric measureSprinkles Drops Drops Combined once daily 3x/day Weight-for-age z-score Baseline -1.49 (1.05) -1.54-1.38 -1.48 (1.15) (1.09) (1.10) Final -1.53 (0.97) -1.53-1.42 -1.49 (1.13) (1.06) (1.06) P 0.26 0.78 0.26 0.14 Height-for-age z-score Baseline -1.32 (1.07) -1.44-1.38 -1.36 (1.14) (1.09) (1.12) Final -1.47 (1.04) -1.60-1.53 -1.53 (1.28) (1.14) (1.16) P 0.0001 0.025 0.0003 <0.0001 Weight-for-height-for-age z-score Baseline -0.80 (0.90) -0.74-0.66 --0.74 (0.97) (0.93) (0.94) Final -0.81(0.93) -0.66--0.58 -0.68 (0.88) (0.95) (0.92) P 0.97 0.11 0.16 0.095 Data are mean (SD). *Defined as the mean for all treatment groups.
Example S - Composition containing Microencaosulated Iron and Vitamin A
500 mg sachets each containing a 40 mg dose of iron and a 2000 ILJ dose of vitamin A as retinol acetate (supplied by Hoffmann-La Roche) were prepared by mixing the SUBSTITUTE SHEET (RULE26) WO Ot/I5714 PCT/CA00/00990 following ingredients. The descote ferrous fumarate, ascorbic acid and excipient were supplied as desc~bed in Example 1.
Dose Inyfedient g/l~,e sachet 40 mg Fe Descote ferrous fumarate 405.60 0.2028 50 mg Ascorbic acid 100.00 0.05 2000 IU Retinol Acetate 6.72 0.00336 Excipient 487.68 0.24384 TOTAL 1000.00 0.5 2000 sachets per kg of composition each containing 0.5g were filled as a single fill.
Example 6: Composition containing microencapsulated iron 500 mg sachets each containing a 40 mg dose of iron were prepared by mixing the 15 following ingredients. The descote ferrous fumarate, ascorbic acid and excipient were supplied as described in Example 1.
Dose InygLrediem gLka e/sachet 40 mg Descotc ferrous fumarate 405.60 0.2028 SO mg Ascorbic acid 100.00 0.05 Excipient 494.40 0.2472 TOTAL 1000.00 0.5 2000 sachets per kg of composition each containing O.Sg were f Iled as a single fill.
25 Example 7: -Randomized controlled trial to determine the effect of frequency of dosingand form of iron on the treatment of iron deficiency anemia.
437 infants (8 to 18 months t 2 weeks) who 'graduated' from the study as described in Example 4 without iron deficiency anemia (hgb > 99 g/L) were recruited into this SUBSTITUTE SHEET (RULE26) wo oms~t4 Pcricnooioor~o randomized double-blind controlled trial to determine the efficacy of micro-encapsulated ferrous fumarate retinyl palmitate sprinkles in preventing iron deficiency anemia and vitamin A deficiency when used daily in weaning foods. Parents were approached to enroll their infants in the study at the end of the study descr;bed in Example 4, After informed consent from the parents) was received, infants were randomized to one of the 4 groups (if the hemoglobin is < 100 g/1). The positive control group was given ferrous sulfate drops. The negative cantrol group received the a placebo sachet containing 0.5 grams of excipient (described in Example 1) with a small amount of brown rice.with periodic vitamin A supplements, while the third group received the iron and vitamin A sachets described in Example S and the fourth group received iron alone sachets as described in Example 6.
All parents were given the same simple instructions on daily use of sachets (ie "EMPTY THE CONTENTS OF ONE PACKET (SACHET) OIV TO THE BABY'S
FOOD (cereal, etc). ONLY USE ONE PACKET EACH DAY"). Each family mct with a research assistant at least monthly for 6 months. At each visit, a questionnaire was administered with questions concerning general health, food intake, compliance and ease of use of the sachets (see data management manual for the questionnaires that will be used in the study). Infants also had their length, weight and head circumference measured at each visit. At each visit enough sachets were distributed to last until the next visit. A second blood sample (200 -300 ftl) was drawn at the end of the study to assess haematologic and vitamin A status (as previously described).
Vitamin A End-Point If a serum retinol concentration less than 0,7~tmol/I is detected, no specific individual therapy is recommended unless clinical signs of deficiency are concurrently detected.
The WHO/L1NICEF/IVACG Task Force on vitamin A supplements recommends this policy.
SUBSTITUTE SHEET (RULE26) WO Ot/15714 PCT/CA00/00990 Statistical Analysis The principal outcomes were the efficacy of iron-vitamin A sprinkles in the prevention of anemia (Groups A, B and C versus D; B vs C); and prevention of vitamin A deficiency (Groups B versus A and C). To determine if there is a difference 5 in the proportion of infants with anemia treated with iron from drops or sachets, groups B and C were compared to group A. Analysis was completed by comparing the proportion of infants from each group reaching end points using Chi-square analysis. Secondary outcomes included: (i) the effect of age on prevalence of anemia by group; and (ii) the effect of group on hemoglobin response. Logistic regression 10 and survival analysis was also completed on outcome data. The table below shows the comparisons.
Table 6: Study Groups Efficacy Study Group Statistical Comparisons Iron drops - +ve controlA A, B, & C vs D
Iron + Vitamin A (sachet)B 8 vs A &C
Iron Alone (sachet) C B& C vs A
Bxcipient only (sachet)D A, B, & C vs -ve D
control xample 8: Composition containing_microencapsulated iron and zinc 1 g sachets each containing a 40 mg iron and 10 mg zinc dose were prepared as described in the preceding examples, containing the following ingredients, supplied as described in the preceding examples.
SUBSTITUTE SHEET {RULE26) Dose In,g_redient g~ke e/sachet 40 mg Fe Descote ferrous furnarate405.60 0.2028 mg Zn Zinc gluconate dehydrate76.10 0.0761 50 mg Ascorbic acid 50.00 0.05 5 Excipient 468.30 0.4683 TOTAL 1000.00 1.0 1000 sachets per kg of composition each containing 1g were filled as a single fill.
l0 Example 9 - Composition Containing Micronutrients and Probiotics 0.5 g sachets were prepared with the following ingredients L. rhamnosus + L. acidophiius (encapsulated, Supplied by Institut Rosell-Lallemand Inc., Montreal)cfu 2 X
l06 FOS(supplied by Institut Roselt-Laltemand Inc., Montreal) 40 mg/sachet Vitamin C 50 mg Vitamin A (as acetate) 3000 IU
Descote ferrous fumarate) 60 mg Iron (as ferric sodium EDTA) (Lohmann Inc., Emmerthal, Germany) 2.4 mg zinc gluconate 10 mg Example 10 - Pilot Study to Determine the Efficiency of the Composition Containin Micronutrients and Probiotics in Reducing the Incidence and Prevalence of Diarrhea The composition of example 9 is tested in a double-blind, randomized control trial to investigate the efficiency of the composition of zinc, iron, ascorbic acid and vitamin A
and probiotics in reducing the incidence and prevalence of diarrhea. Infants receive one of 3 interventions, described below. The compositions are sprinkled over or SUBSTITUTE SHEET (RULE26) wo oms~i4 pcric~ooroo~o added to infant weaning foods after the foods have been cooked. It is not a component of the food before the food is cooked. It is not added to the food during the cooking process.
Table 7. Intervention Groups Intervention Grou 'Sprinkles' Ingredient Fe SprinklesFe + Zn SprinklesFe + Zn +
Pro-b (control) Sprinkles n=314 as in example n=314 n=314 Iron (as ferrous fumarate and FeNa EDTA) m 60 60 60 Ascorbic Acid (m 40 40 40 ) Retinol Acetate 2000 2000 2000 (ICJ) Zinc - 10 10 Probiotic (CFU) - - 1-2 x 10 IO Therefore all three treatment groups contain the standard sprinkles ingredients; iron, vitamin C and A. To one group zinc is added to the sachets and to another group, zinc and probiotics. This allows us to compare the rates of diarrhea among the three groups.
There is no true placebo group. In order to recnrit a representative sample population of infants into the study, anemic as well as non-anemic infants enter the study. A
secondary outcome measure in this study is hemoglobin values. Hemoglobin can be directly determined in the field using HemocuesT"'. Therefore, we identify those infants that are anemic (hemoglobin < 10 g/dL). It would be unethical to randomize infants with anemia into a placebo group where they would not be provided with iron supplementation. Therefore all infants in the study will receive iron.
SUBSTITUTE SHEET (RULE26}
Infants who are 6 to 18 months of age at time of recruitment, ingesting a weaning food in addition to breast milk, hemoglobin >6.9 g/dL, whose family expects to remain in the vicinity (town, hospital clinic area, etc for 8 months), and who have parental consent are included in the study. Infants <5.5 months of age, sickle cell disease, or with hemoglobin c 7.0 g/dL (infants with severe anemia are referred for evaluation and treatment) are excluded.
The primary outcome measures are incidence and prevalence of diarrhea (the number of new episodes of the illness and the days with the illness, respectively, per total days of observation). A day of diarrhea was defined as a 24 hour period with 3 or 4 unformed StOOIS. An episode of diarrhea was defined as at least 1 day of diarrhea.
with the final day of the episode being the last day meeting the diarrhea definition followed by at least 48 hours without diarrhea. An episode of dysentery was defined as an illness meeting the definition of diarrhea in which blood was observed in the stools. An episode of persistent diarrhea was defined as diarrheal illness that lasted I S >= 14 days.
The secondary outcomes measures include hemoglobin concentration, plasma zinc concentration, anthropometry (weight for height, age for height Z scores), and general health and morbidity data.
Infants are randomly assigned to one of the 3 intervention groups. The infants receive their assigned sprinkles sachet daily for a period of 12 months. Morbidity surveillance field workers visit the child at home weekly to deliver sachet supplies and record information on the number of diarTheal stools, consistency of stools, fever, vomiting, feeding history and compliance data. At baseline and final visit at 12 months.
anthropometry measurements and hemoglobin values are assessed. A small capillary blood satnpie (500 ~L) is collected at baseline and final visits to determine plasma zinc concentration.
SUBSTITUTE SHEET (RULE Z6) wo omsm4 pcrrcnooroo~o Analysis of variance is used to look at differences in the incidence and prevalence of diarrhea between groups. Paired t-tests are used to assess change in anthropornetry, plasma zinc and hemoglobin over time. Anthropometric measures are converted to z-scores using the NCHS reference standards. Analysis is conducted using SAS
6.12 (SAS Institute, Inc., Carey, NC). The acceptable level of statistical significance for all tests is p<O.OS.
SUBSTITUTE SHEET (RULE26) wo omsn4 Pcric~ooroo~o 1. Bhan et al., "The Role of Zinc and Vitamin A in Persistent Diarrhea Among Infants and Young Children", Journal of Pediatric Gastroenterology and Nutrition, 5 1998, 26 : 446-453 2. Sazawal, et al. "Zinc Supplementation Reduces the Incidence of Acute Lower Respiratory Infections in Infants and Preschool Children: A Double-blind, Controlled Trial", Pediatrics, July 1998, 102 (No. 1): 1-5 3. Collins et al., "Probiotics, Prebiotics and Symbiotics: Approaches for Modulating Ecology of the Gut" American Joumat of Clinical Nutrition, 1999, 69 (Suppl}
4. Gibson et al., "Dietary modulation of the human colonic microbiota:
introducing the concept of prebiotics." J Nutrition 1995; 125: 1401-12 5. Fuller R. ed. Probiotics: the scientific basis, London: Chapman and Hall, G. Saavedra J.M., "Microbes to fight microbes: a not so novel approach for controlling diatrheal disease", Journal of Pediatric Gastrocnterology and Nutrition, 1995, 21: 125-9 7. Isolauri E. et al., "A human lactobacillus strain (Lactobacillis casei sp.
Strain GG) promotes recovery from acute diarrhea in children", Pediatrics 1991, 88: 90-7 SUBSTITUTE SHEET (RULE26) wo ovt sm4 36 PcrrcAOOroo99o 8. Fritz et al., Journal of the Association of O»cial Analytical Chemists (AOAC), 1974, 57: 513-517 and by Williams in the Official methods of analysis of the AOAC, 14~' edition, Arlington VA, AOAC, 1984, p. 880-881 9. Davidsson et a1. "Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate". Am J Clin Nutr 2000 71: 1597-1602 SUBSTITUTE SHEET (RULE26)
ProbiocapT"" is encapsulated by coating in a matrix of food-grade vegetable fatty acids. In the past, probiotics had to be kept refrigerated in order to maintain the viability of the bacteria culture. Traditional freeze-dried probivtic bacteria are 20 sensitive to high moisture, extreme temperatures and other physical and chemical stresses. This sensitivity limits their use in many applications. Their viability also decreases during digestion due to the extreme gastric acidity which has long been a concern. Probiotic applications, including the provision of probiotics in non-refrigerated sachets, was limited due to elevated temperatures and the presence of 25 oxygen and moisture that would adversely affect survival rates.
SUBSTITUTE SHEET (RULE Z6) wo ovisma Pcric~ooroo~o 1g It will be appreciated that there is no restriction on the foods or beverages to which the present composition can be added. Since the present composition is particularly beneficial for use in the prevention of anemia in infants and young children, the composition will typically be added to foods and beverages generally consumed by infants and young children. )rxampies of such foods include pureed or semi-solid foods, for example cereals, gtvels, porridges, purees of fruit, vegetables, meat or mixtures thereof, as well as milk-based products including, but not strictly limited to, milk, powdered milk, infant formula, puddings, yogurt, creamed cheese, cottage cheese, and other dairy products which form a part of the diet of infants and young children. The term milk-based products is also meant to include milk substitutes including lactose-free milk and associated products, soy milk and the like.
In a preferred embodiment, a single daily dosage of the composition is packaged, for example in a sachet-type package, comprising about 60 mg of elemental iron in the form of micro-encapsulated granules, prebiotics and probiotics in therapeutically effective amounts, which are known to those skilled in the art , for example, 1 to 2 x 106 colony forming units (CFUs) of probiotics and about 400-mg of excipient. In a particularly preferred embodiment, the package will additionally include ascorbic acid in an amount of about 20-I00 mg, iodine in an amount of 20-100 pg, and vitamin A in an amount of 50-2500 ILI.
A method for enhancement of general immunity in a mammal is also provided. The method involves the steps of adding a therapeutically effective amount of the present composition to a food, and then administering the food to the mammal requiring treatment. The term "therapeutically effective" as it is used with respect to the present composition refers to an amount which is effective to prevent iron deficiency anemia, or at least minimize the occurrence of adverse effects related thereto, while not exceeding an amount which would be toxic or otherwise harmful. In this regard, precise dosage sizes appropriate to prevent anemia can readily be established in SUBSTITUTE SHEET (RULE26) appropriately controlled trials.
The present invention is described in more detail by reference to the following specific examples which are not to be construed as limiting.
S
Example 1 - Preparation of an Iron-containin Composition Encapsulated ferrous fumarate 60% (1 gram delivers 600 mg ferrous fumarate) (Descote~ Ferrous Furnarate 60), having a particle size of no more than about microns in which about 99% of the particles pass through a U. S. No. 20 sieve, was obtained from Particle Dynamic lnc, St. Louis, MO.
Ascorbic acid (3.5 kg; obtained from Basf) was thoroughly mixed in a large aluminum bowl with an excipient (25 kg; obtained from New Dundee Creamery, Division of Ault Foods Limited) containing corn syrup solids, hydrogenated vegetable oil and/or hydrogenated coconut oil, sodium caseinate, potassium phosphate di-basic, sodium phosphate di-basic, mono and diglycerides, acetylated tartaric acid esters of monoglycerides, artificial colour, and natural and artificial flavour.
In a 2-stage fill, 200 mg aliquots of encapsulated ferrous furnarate were added to foil-lined sachet packets followed by the addition of 300 mg of ascorbic acid/excipient mixture. The sachets were appropriately sealed along their open edge.
Optionally, 2.1 kg zinc gluconate is admixed with the ascorbic acid and excipient.
This mixture is then added to ferrous fumarate-containing sachets as set out above.
Example 2 -Relative Bioavailability of Micro-encapsulated Iron SUBSTITUTE SHEET (RULE26) The bioavailability of iron in the composition set out in Example I has been determined using the hemoglobin-repletion test in rats as follows.
5 Male weanling Sprague-Dawley rats housed individually in stainless steel cages were fed a low iron diet and de-ionized distilled water ad lib for 24 days.
The low-iron diet contained no more than about 3 mg of iron per kg of diet. Follomng the 24 day depletion period, approximately 200 ltl of blood was drawn from the tail vein of each rat for hemoglobin analysis. Anemic rats having hemoglobin values 10 between 30 and 60 gJL were used in the study. The rats were housed individually in cafes in a randomized block design. The rats were divided into groups. each group being fed ad libitum a test diet selected from 0, 1U or 20 mg of one of microencapsulated or coated ferrous fumarate (prepared as described in Example 1), microencapsulated or coated ferrous fumarate with zinc, uncoated ferrous fumarate 15 panicles or uncoated ferrous sulphate (a reference compound detertrrined to have a relative bioavailability of 100) per kilogram of diet. The test groups are more specifically set out in the following Table 2:
Table 2: Bioavailability Test Groups # of Ferrous SulfateCoated Coated FerrousFerrous Animals (Fe S047H20)Ferrous Fumarate+ZincFumarate Fulnarate 10 t0 mg Fe/kg 0 0 0 diet 10 20 mg Felkg 0 0 0 SUBSTI?UTE SHEET (RULE26) WO 01115714 PCf/CA00/00990 z1 diet 0 10 mg Fe/kg 0 0 diet 10 0 20 mg Felkg 0 0 diet 10 0 0 0 Fe; 10 mg/kg0 Zn 10 0 0 10 Fe; 10 0 mg/kg Zn 10 0 0 20 Fe; 10 0 mg/kg Zn 10 0 0 0 10 mg Fe/kg diet 10 0 0 0 20 mg Fe/kg diet Total The results, as shown in Figure 1, indicate that hemoglobin response is dependent on the amount of iron in the rat's diet. Moreover, there was no significant difference in 5 the hemoglobin response between rats fed similar amounts of iron as the reference compound (ferrous sulfate) versus rats fed micro-encapsulated ferrous fumarate.
Referring to Fig. 1, the control group represents rats fed a diet containing no iron, the "low iron" diet represents a diet containing 10 mg micro-encapsulated ferrous 10 fumarate/kg of diet, the "high iron control" diet represents a diet containing 20 mg ferrous sulfate/kg of diet and the "high iron" diet represents a diet containing 20 mg SUBSTITUTE SHEET (RULE26) micro-encapsulated ferrous fumarate/kg of diet. There was no change in the hemoglobin of the control after 14 days of feeding, while mean hemoglobin response of the low iron diet group was 18 g/L and the mean hemoglobin response of the high iron control and high iron diet groups was 31 g/L and 33 g/L, respectively.
Example 3 - Preparation of sachets containing 80me iron and 50 mg ascorbic acid For an 80 mg dose of iron, and a SOmg dose of ascorbic acid, the following ingredients were supplied as described in Example 1 and put together and mixed thoroughly. Sachets were filled as a single fill, with 1000 1 gram sachets obtained per kg of raw materials.
Dose I~e~redient ~~Lks Q/sachet 80 mg Descote Ferrous Fumarate 405.60 0.4056 40 mg Ascorbic acid ( 10l0 overage)50.00 0.05 Excipient 544.40 0.5444 TOTAL 1000.00 1.00 Example 4 - Randomised controlled trial of microencapsulated ferrous fumarate sprinkles and ferrous sulphate tops for treatment of anaemia in Ghanaian infants and youne children The effectiveness of the composition of example 3 (referred to as "sprinkles") in treating anaemia in infants and young children has been determined as follows:
In a randomised controlled trial, 837 children (age range 6-24 months:
haemoglobin values 70-99 g/L) were studied. The children were selected from rural villages of SUBSTITUTE SHEET (RULE26) WO 01/15714 PC'f/CA00/00990 Kintampo, Ghana, a malaria-endemic area. One treatment group (n=280) received a daily sachet as described in example 3, containing microencapsulated ferrous fumarate (80 mg elemental iron) plus ascorbic acid; another (n=280) ferrous sulphate drops once daily (40 mg elememal iron); and the control group (n=277) ferrous sulphate drops three times per day (total dose 40 mg elemental iron). Treatment lasted for 2 months. Haemoglobin and serum ferritin values were measured at baseline and 2 months later.
Field workers visited infants at 2-week intervals after the baseline visit, for a total of 5 visits. During the baseline assessment, a written questionnaire was administered to collect demographic, nutritional, and health data for each infant. During the final visit and each of the 2-week visits, a questionnaire about the side effects and compliance over the preceding 7 days (eg, a question about how often the child received drops in the last 7 days) was completed. Data collected about side effects included the 1 S incidence of diarrhea, constipation, and genera) discomfort after ingestion of the coated iron or iron drops. Questions about adherence to treatment included whether the children objected to taking the iron and whether microencapsulated ferrous fumarate changed the colour or consistency of the infants' food. Fieldworkers provided parents with oral educational reinforcement to maximize adherence to the treatment.
Anthropometric measurements, including weight for age, height for age, and weight for height for age, were completed during baseline and final visits. An infant-length board with a sliding foot-board was used for measurement of the child's body length, and a hanging scale graduated in 100-g divisions, for weight measurements. Two fieldworkers completed the measurements in duplicate using standardized techniques.
Capillary blood samples at baseline and final visits were obtained from a finger prick using aseptic techniques, and haemoglobin was measured on the spot with portable SUBSTITUTE SHEET (RULE26) wo ams~t4 rcric~ooioo~o Hemocue photometers (Hemocue Inc, Angelholm, Sweden). Malaria parasite smears were taken (at baseline only), and 500 p.L blood samples were collected and preserved in ice-lined cold boxes. Blood samples were returned to the base station within 6 hours of collection, where the serum was separated by centrifugation (10 minutes at 1300 RPM) before storage at -40°C. Serum ferntin was assayed in duplicate by a commercial enzyme-linked immunosorbent assay (ELISA), using a Spectro Ferritin Kit (Ramco Laboratories, Houston, TX). ~4 Baseline and final ferritin samples from an individual subject were assayed on the same day (in a single batch) on one 96-well microtitre plate to minimise inter-assay variation. An external reference standard (Lyphochek Anaemia Control, Bio-Rad, Anaheim, CA) was assayed in duplicate on each microtitre plate for the ferritin assay.
The blood films were stained and examined for malaria parasites at the end of the study. Children whose blood films indicated a possible malaria infection were treated at home for malaria. Children who were severely anaemic (haemoglobin <70 g/I,) were excluded from the trial and treated.
Those children in the positive control group were given ferrous sulphate drops (5 mg/kg/day of elemental iron, rounded to a total of 40 mg of elemental iron) provided in three equal doses per day. The other two groups received either the ferrous sulphate drops (40 mg) provided daily in a single bolus or microencapsulated ferrous fumarate (80 mg of elemental iron) in the composition of Example 3 packaged in a sachet with ascorbic acid (50 mg), called sprinkles sachets, and added to tire child's meal serving (after it was cooked) once daily.
Children were individually randomised to one of the three treatment groups.
Randomisation was done with sealed opaque envelopes containing group designations, which were generated randomly by computer with Microsoft Access (Microsoft Corporation, Seattle, WA). It was not feasible to blind the field staff or the SUBSTITUTE SHEET (RULE26) WO 01/15114 p~yCApp~ppggp mothers to the group to which the children were assigned. However, the persons responsible for the laboratory and data analyses were blinded to the group designations.
5 Haemoglobin In all groups, there was a significant increase in haemoglobin concentrations from baseline to the end of the study (p<0.001; table 1 ). The change in haemoglobin concentrations (from baseline to final) was similar among treatment groups.
Successful treatment of anaemia (hemoglobin > 100 g/L) occurred in 58°~to in the 10 sprinkles group, in 619'0 of the once-a-day drops group, and in 56°0 of the control group. There was no significant difference between these (p~.51). Ferritin levels increased significantly in each group (p<0.001) although less so in the sprinkles group. Tfie relative risk of remaining anaemic after 2 months of treatment was 1.03 times greater for the sprinkles group (95°lo CI 0.88-1.20, p=0.?5) and 0.92 times 15 lower for once-daily ferrous sulphate group (95% CI 0.79-1.06, p=0.26) than that for the three-times-daily fen;ous sulphate group, but the differences were not significant.
Infants who were positive for malaria were more likely to be anaemic at the end of two months in all groups. The relative risk of remaining anaemic after 2 months of treatment was 1.23 times greater for those with malaria (95Ro CI 1.10-1.37, p~.0006) 20 than those who were malaria-free. The mean haemoglobin values are set out in the following table.
Table 3: Mean haemoglobin (g/L) by treatment group at baseline and after 2 months Treatrncnt group Haemoglobin Sprinkles Drops Drops values (g/L) once daily 3x/day Mean (SD) at Baseline 87 (8) 88 (8) 87 (8) SUBSTITUTE SHEET (RULE26) WO Ol/15714 PCT/CA00/00990 Final 102 (16) 102 (18) 100 (17) Ferritin The geometric mean ferritin values at baseline were similar in all grnups (table 2).
There was a significant increase (around two-fold or more) after 2 months of treatment (p<0.0001); however, the values in both drops gmups were significantly higher than those in the sprinkles group. The variance for ferritin values was quite wide at both baseline and the end of the study as is usual with the wide inter-individual and analytic variance associated with this measure. The ferritin values are set out in the following table.
Table 4: Geometric mcan ferritin values (ltg/L) by treatment group at baseline and after 2 months of intervention Treatment group Fenritin Sprinkles Drops Drops values (pg/i,) once daily 3x/day Baseline 42.9 (99.4) 34.8 (74.8) 45.5 (83.5) Final 81.1 (I40.9j 102.1 (l13 ~) 111.0 (132.1) IS Data are geometric means (SD): analysis was done with log-transformed values since fetritin values are not normally distributed. Mean ferntin increased significantly from baseline to the final visit in all treatment groups (p<0.001). Mean ferritin value at final sampling was significantly lower (pt0.05) from both drops groups. Normal range for ferritin is 12 - 80~tglL for infants 6 to 24 months of age (23) Anthropometric measurements At baseline all infants had similar weight for age z-scores (mean [SD] -1.48 [1.10]), height for age (-1.36 [1.12]) and weight for height (-0.74 [0.94]). No effect of SUBSTITUTE SHEET (RULE26) treatment was found for weight for age and weight for height for age. There was a significant decrease in height-for-age z-scores in all three groups from baseline to the final measurements (mean [SDj change -0.16 [0.79], p<0.001). The anthropometric measurements are set out in the following table.
Table 5: Anthropometric measurements for each treatment group at baseline and after 2 months of intervention Treatment groups Anthropometric measureSprinkles Drops Drops Combined once daily 3x/day Weight-for-age z-score Baseline -1.49 (1.05) -1.54-1.38 -1.48 (1.15) (1.09) (1.10) Final -1.53 (0.97) -1.53-1.42 -1.49 (1.13) (1.06) (1.06) P 0.26 0.78 0.26 0.14 Height-for-age z-score Baseline -1.32 (1.07) -1.44-1.38 -1.36 (1.14) (1.09) (1.12) Final -1.47 (1.04) -1.60-1.53 -1.53 (1.28) (1.14) (1.16) P 0.0001 0.025 0.0003 <0.0001 Weight-for-height-for-age z-score Baseline -0.80 (0.90) -0.74-0.66 --0.74 (0.97) (0.93) (0.94) Final -0.81(0.93) -0.66--0.58 -0.68 (0.88) (0.95) (0.92) P 0.97 0.11 0.16 0.095 Data are mean (SD). *Defined as the mean for all treatment groups.
Example S - Composition containing Microencaosulated Iron and Vitamin A
500 mg sachets each containing a 40 mg dose of iron and a 2000 ILJ dose of vitamin A as retinol acetate (supplied by Hoffmann-La Roche) were prepared by mixing the SUBSTITUTE SHEET (RULE26) WO Ot/I5714 PCT/CA00/00990 following ingredients. The descote ferrous fumarate, ascorbic acid and excipient were supplied as desc~bed in Example 1.
Dose Inyfedient g/l~,e sachet 40 mg Fe Descote ferrous fumarate 405.60 0.2028 50 mg Ascorbic acid 100.00 0.05 2000 IU Retinol Acetate 6.72 0.00336 Excipient 487.68 0.24384 TOTAL 1000.00 0.5 2000 sachets per kg of composition each containing 0.5g were filled as a single fill.
Example 6: Composition containing microencapsulated iron 500 mg sachets each containing a 40 mg dose of iron were prepared by mixing the 15 following ingredients. The descote ferrous fumarate, ascorbic acid and excipient were supplied as described in Example 1.
Dose InygLrediem gLka e/sachet 40 mg Descotc ferrous fumarate 405.60 0.2028 SO mg Ascorbic acid 100.00 0.05 Excipient 494.40 0.2472 TOTAL 1000.00 0.5 2000 sachets per kg of composition each containing O.Sg were f Iled as a single fill.
25 Example 7: -Randomized controlled trial to determine the effect of frequency of dosingand form of iron on the treatment of iron deficiency anemia.
437 infants (8 to 18 months t 2 weeks) who 'graduated' from the study as described in Example 4 without iron deficiency anemia (hgb > 99 g/L) were recruited into this SUBSTITUTE SHEET (RULE26) wo oms~t4 Pcricnooioor~o randomized double-blind controlled trial to determine the efficacy of micro-encapsulated ferrous fumarate retinyl palmitate sprinkles in preventing iron deficiency anemia and vitamin A deficiency when used daily in weaning foods. Parents were approached to enroll their infants in the study at the end of the study descr;bed in Example 4, After informed consent from the parents) was received, infants were randomized to one of the 4 groups (if the hemoglobin is < 100 g/1). The positive control group was given ferrous sulfate drops. The negative cantrol group received the a placebo sachet containing 0.5 grams of excipient (described in Example 1) with a small amount of brown rice.with periodic vitamin A supplements, while the third group received the iron and vitamin A sachets described in Example S and the fourth group received iron alone sachets as described in Example 6.
All parents were given the same simple instructions on daily use of sachets (ie "EMPTY THE CONTENTS OF ONE PACKET (SACHET) OIV TO THE BABY'S
FOOD (cereal, etc). ONLY USE ONE PACKET EACH DAY"). Each family mct with a research assistant at least monthly for 6 months. At each visit, a questionnaire was administered with questions concerning general health, food intake, compliance and ease of use of the sachets (see data management manual for the questionnaires that will be used in the study). Infants also had their length, weight and head circumference measured at each visit. At each visit enough sachets were distributed to last until the next visit. A second blood sample (200 -300 ftl) was drawn at the end of the study to assess haematologic and vitamin A status (as previously described).
Vitamin A End-Point If a serum retinol concentration less than 0,7~tmol/I is detected, no specific individual therapy is recommended unless clinical signs of deficiency are concurrently detected.
The WHO/L1NICEF/IVACG Task Force on vitamin A supplements recommends this policy.
SUBSTITUTE SHEET (RULE26) WO Ot/15714 PCT/CA00/00990 Statistical Analysis The principal outcomes were the efficacy of iron-vitamin A sprinkles in the prevention of anemia (Groups A, B and C versus D; B vs C); and prevention of vitamin A deficiency (Groups B versus A and C). To determine if there is a difference 5 in the proportion of infants with anemia treated with iron from drops or sachets, groups B and C were compared to group A. Analysis was completed by comparing the proportion of infants from each group reaching end points using Chi-square analysis. Secondary outcomes included: (i) the effect of age on prevalence of anemia by group; and (ii) the effect of group on hemoglobin response. Logistic regression 10 and survival analysis was also completed on outcome data. The table below shows the comparisons.
Table 6: Study Groups Efficacy Study Group Statistical Comparisons Iron drops - +ve controlA A, B, & C vs D
Iron + Vitamin A (sachet)B 8 vs A &C
Iron Alone (sachet) C B& C vs A
Bxcipient only (sachet)D A, B, & C vs -ve D
control xample 8: Composition containing_microencapsulated iron and zinc 1 g sachets each containing a 40 mg iron and 10 mg zinc dose were prepared as described in the preceding examples, containing the following ingredients, supplied as described in the preceding examples.
SUBSTITUTE SHEET {RULE26) Dose In,g_redient g~ke e/sachet 40 mg Fe Descote ferrous furnarate405.60 0.2028 mg Zn Zinc gluconate dehydrate76.10 0.0761 50 mg Ascorbic acid 50.00 0.05 5 Excipient 468.30 0.4683 TOTAL 1000.00 1.0 1000 sachets per kg of composition each containing 1g were filled as a single fill.
l0 Example 9 - Composition Containing Micronutrients and Probiotics 0.5 g sachets were prepared with the following ingredients L. rhamnosus + L. acidophiius (encapsulated, Supplied by Institut Rosell-Lallemand Inc., Montreal)cfu 2 X
l06 FOS(supplied by Institut Roselt-Laltemand Inc., Montreal) 40 mg/sachet Vitamin C 50 mg Vitamin A (as acetate) 3000 IU
Descote ferrous fumarate) 60 mg Iron (as ferric sodium EDTA) (Lohmann Inc., Emmerthal, Germany) 2.4 mg zinc gluconate 10 mg Example 10 - Pilot Study to Determine the Efficiency of the Composition Containin Micronutrients and Probiotics in Reducing the Incidence and Prevalence of Diarrhea The composition of example 9 is tested in a double-blind, randomized control trial to investigate the efficiency of the composition of zinc, iron, ascorbic acid and vitamin A
and probiotics in reducing the incidence and prevalence of diarrhea. Infants receive one of 3 interventions, described below. The compositions are sprinkled over or SUBSTITUTE SHEET (RULE26) wo oms~i4 pcric~ooroo~o added to infant weaning foods after the foods have been cooked. It is not a component of the food before the food is cooked. It is not added to the food during the cooking process.
Table 7. Intervention Groups Intervention Grou 'Sprinkles' Ingredient Fe SprinklesFe + Zn SprinklesFe + Zn +
Pro-b (control) Sprinkles n=314 as in example n=314 n=314 Iron (as ferrous fumarate and FeNa EDTA) m 60 60 60 Ascorbic Acid (m 40 40 40 ) Retinol Acetate 2000 2000 2000 (ICJ) Zinc - 10 10 Probiotic (CFU) - - 1-2 x 10 IO Therefore all three treatment groups contain the standard sprinkles ingredients; iron, vitamin C and A. To one group zinc is added to the sachets and to another group, zinc and probiotics. This allows us to compare the rates of diarrhea among the three groups.
There is no true placebo group. In order to recnrit a representative sample population of infants into the study, anemic as well as non-anemic infants enter the study. A
secondary outcome measure in this study is hemoglobin values. Hemoglobin can be directly determined in the field using HemocuesT"'. Therefore, we identify those infants that are anemic (hemoglobin < 10 g/dL). It would be unethical to randomize infants with anemia into a placebo group where they would not be provided with iron supplementation. Therefore all infants in the study will receive iron.
SUBSTITUTE SHEET (RULE26}
Infants who are 6 to 18 months of age at time of recruitment, ingesting a weaning food in addition to breast milk, hemoglobin >6.9 g/dL, whose family expects to remain in the vicinity (town, hospital clinic area, etc for 8 months), and who have parental consent are included in the study. Infants <5.5 months of age, sickle cell disease, or with hemoglobin c 7.0 g/dL (infants with severe anemia are referred for evaluation and treatment) are excluded.
The primary outcome measures are incidence and prevalence of diarrhea (the number of new episodes of the illness and the days with the illness, respectively, per total days of observation). A day of diarrhea was defined as a 24 hour period with 3 or 4 unformed StOOIS. An episode of diarrhea was defined as at least 1 day of diarrhea.
with the final day of the episode being the last day meeting the diarrhea definition followed by at least 48 hours without diarrhea. An episode of dysentery was defined as an illness meeting the definition of diarrhea in which blood was observed in the stools. An episode of persistent diarrhea was defined as diarrheal illness that lasted I S >= 14 days.
The secondary outcomes measures include hemoglobin concentration, plasma zinc concentration, anthropometry (weight for height, age for height Z scores), and general health and morbidity data.
Infants are randomly assigned to one of the 3 intervention groups. The infants receive their assigned sprinkles sachet daily for a period of 12 months. Morbidity surveillance field workers visit the child at home weekly to deliver sachet supplies and record information on the number of diarTheal stools, consistency of stools, fever, vomiting, feeding history and compliance data. At baseline and final visit at 12 months.
anthropometry measurements and hemoglobin values are assessed. A small capillary blood satnpie (500 ~L) is collected at baseline and final visits to determine plasma zinc concentration.
SUBSTITUTE SHEET (RULE Z6) wo omsm4 pcrrcnooroo~o Analysis of variance is used to look at differences in the incidence and prevalence of diarrhea between groups. Paired t-tests are used to assess change in anthropornetry, plasma zinc and hemoglobin over time. Anthropometric measures are converted to z-scores using the NCHS reference standards. Analysis is conducted using SAS
6.12 (SAS Institute, Inc., Carey, NC). The acceptable level of statistical significance for all tests is p<O.OS.
SUBSTITUTE SHEET (RULE26) wo omsn4 Pcric~ooroo~o 1. Bhan et al., "The Role of Zinc and Vitamin A in Persistent Diarrhea Among Infants and Young Children", Journal of Pediatric Gastroenterology and Nutrition, 5 1998, 26 : 446-453 2. Sazawal, et al. "Zinc Supplementation Reduces the Incidence of Acute Lower Respiratory Infections in Infants and Preschool Children: A Double-blind, Controlled Trial", Pediatrics, July 1998, 102 (No. 1): 1-5 3. Collins et al., "Probiotics, Prebiotics and Symbiotics: Approaches for Modulating Ecology of the Gut" American Joumat of Clinical Nutrition, 1999, 69 (Suppl}
4. Gibson et al., "Dietary modulation of the human colonic microbiota:
introducing the concept of prebiotics." J Nutrition 1995; 125: 1401-12 5. Fuller R. ed. Probiotics: the scientific basis, London: Chapman and Hall, G. Saavedra J.M., "Microbes to fight microbes: a not so novel approach for controlling diatrheal disease", Journal of Pediatric Gastrocnterology and Nutrition, 1995, 21: 125-9 7. Isolauri E. et al., "A human lactobacillus strain (Lactobacillis casei sp.
Strain GG) promotes recovery from acute diarrhea in children", Pediatrics 1991, 88: 90-7 SUBSTITUTE SHEET (RULE26) wo ovt sm4 36 PcrrcAOOroo99o 8. Fritz et al., Journal of the Association of O»cial Analytical Chemists (AOAC), 1974, 57: 513-517 and by Williams in the Official methods of analysis of the AOAC, 14~' edition, Arlington VA, AOAC, 1984, p. 880-881 9. Davidsson et a1. "Iron bioavailability in infants from an infant cereal fortified with ferric pyrophosphate or ferrous fumarate". Am J Clin Nutr 2000 71: 1597-1602 SUBSTITUTE SHEET (RULE26)
Claims (25)
1. ~A composition useful for enhancing general immunity comprising: at least one micronutrient in a bioavailable form; one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient.
2. ~The composition of claim 1, wherein the at least one micronutrient is selected from the group of iron, iodine, vitamin A, and zinc.
3. ~The composition of claim 2, wherein the composition comprises iron, vitamin A, and zinc.
4. ~The composition of claim 2, wherein the composition comprises iron, iodine, vitamin A, and zinc.
5. ~The composition as in any of claims 3 and 4 wherein the composition additionally comprises FeNaEDTA.
6. ~The composition of claim 1 wherein the pharmaceutically acceptable excipient is a lipid-based excipient.
7. ~The composition of claim 1 wherein the pharmaceutically acceptable excipient is a carbohydrate-based excipient.
8. ~The composition as in any of claims 1-7, wherein the prebiotic is selected from at least one member of the group consisting of FOS, inulin, GOS, lactulose, and lactitol.
9. The composition of claim 8, wherein the FOS is selected from the group of oligofructose and neosugar.
10. The composition as in any of claims 1-7, wherein the probiotic is selected from at least one member of the group consisting of Lactobacilli, Gram-positive cocci, and Bifidobacteria.
11. The composition of claim 10, wherein the Lactobacilli is selected from at least one member of the group consisting of L. acidophus, L. casei, L. delbrueckii subsp.
bulgancus, L. reuteri, L. brevis, L. cellobiosus. L. curvatus, L. fermentum, L.
planaranrm.
bulgancus, L. reuteri, L. brevis, L. cellobiosus. L. curvatus, L. fermentum, L.
planaranrm.
12. The composition of claim 10, wherein the Gram-positive cocci is selected from at least one member of the group consisting of Lactococcus lactis subsp.
thermophilus, Enterrococcus faecium, S. diaacetylactis, S. intermedius.
thermophilus, Enterrococcus faecium, S. diaacetylactis, S. intermedius.
13. The composition of claim 10, wherein the Bifidobacteria is selected from at least 25 one member of the group consisting of B. bifidium, B. adolescentis, B.
animalis, B. infantis, B. longum, B. thermophilum.
animalis, B. infantis, B. longum, B. thermophilum.
14. The composition as in any of claims 1-13, wherein the synbiotic is selected from at least one member of the group consisting of Bifidobacteria + FOS, Lactobacilli + lactitol, and Bifidobacteria + GOS.
15. The composition as in any of claims 1-14, wherein at least one micronutrient is microencapsulated with a compound selected from the group consisting of monoglycerides, diglycerides, ethyl cellulose, hydrogenated soybean oil and mixtures thereof.
16. The composition of claim 15 where the probiotic is encapsulated with one or more compounds selected from the group of waxes, carbohydrates, and lipids.
17. The composition of claim 16 where the probiotic is encapsulated with a lipid.
18. A process for producing a composition useful for enhancing the general immunity of a mammal which consists essentially of the step of combining a micronutrient in a bio-available form with one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic and a pharmaceutically acceptable excipient selected from a group of a lipid-based excipient and a carbohydrate-based excipient.
19. A method for enhancing the general immunity of a mammal comprising the steps of:
a) removing a composition comprising microencapsulated micronutrient~
granules, a substance selected from the group of a prebiotic, probiotic or synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient from packaging material;
b) adding a therapeutically effective amount of said composition to a food; and c) administering the food to said mammal.
a) removing a composition comprising microencapsulated micronutrient~
granules, a substance selected from the group of a prebiotic, probiotic or synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient from packaging material;
b) adding a therapeutically effective amount of said composition to a food; and c) administering the food to said mammal.
20. Use of the composition of any of claims 1-17 for enhancing the general immunity of a mammal.
21. Use of the composition of claim 20, wherein a therapeutically effective amount of the composition is added to food to be administered to the mammal.
22. An article of manufacture including packaging material and a pharmaceutical composition contained within said packaging material which is effective to enhance general immunity, wherein the pharmaceutical composition comprises one or more micronutrients, one or more compounds selected from the group of a prebiotic, probiotic, and synbiotic, and pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient.
23. A method of treating iron deficiency anemia in children comprising:
a) removing a composition comprising iron in a bioavailable form; a substance selected from the group of a prebiotic, probiotic or synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient from packaging material;
b) adding a therapeutically effective amount of said composition to a food;
and c) administering the food to said mammal.
a) removing a composition comprising iron in a bioavailable form; a substance selected from the group of a prebiotic, probiotic or synbiotic, and a pharmaceutically acceptable excipient selected from the group of a lipid-based excipient and a carbohydrate-based excipient from packaging material;
b) adding a therapeutically effective amount of said composition to a food;
and c) administering the food to said mammal.
24. The method of claim 23 where the iron is microencapsulated with a compound selected from the group consisting of monoglycerides, diglycerides, ethyl cellulose, hydrogenated soybean oil and mixtures thereof.
25. The method of claim 24 wherein the composition additionally comprises a micronutrient selected from the group of iodine, vitamin A, and zinc.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002347891A CA2347891A1 (en) | 1999-08-26 | 2000-08-28 | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2,281,463 | 1999-08-26 | ||
CA002281463A CA2281463A1 (en) | 1999-08-26 | 1999-08-26 | Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics |
CA002347891A CA2347891A1 (en) | 1999-08-26 | 2000-08-28 | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics |
PCT/CA2000/000990 WO2001015714A1 (en) | 1999-08-26 | 2000-08-28 | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2347891A1 true CA2347891A1 (en) | 2001-03-08 |
Family
ID=25681187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002347891A Abandoned CA2347891A1 (en) | 1999-08-26 | 2000-08-28 | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2347891A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016198528A1 (en) * | 2015-06-11 | 2016-12-15 | Nestec S.A. | Dietary supplement |
-
2000
- 2000-08-28 CA CA002347891A patent/CA2347891A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016198528A1 (en) * | 2015-06-11 | 2016-12-15 | Nestec S.A. | Dietary supplement |
US20180133267A1 (en) * | 2015-06-11 | 2018-05-17 | Nestec S.A. | Dietary supplement |
US11660322B2 (en) | 2015-06-11 | 2023-05-30 | Societe Des Produits Nestle S.A. | Dietary supplement |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001015714A1 (en) | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics | |
JP6416308B2 (en) | Use of purified 2'-fucosyl lactose, 3-fucosyl lactose, and lactodifucotetraose as prebiotics | |
Serce et al. | Efficacy of Saccharomyces boulardii on necrotizing enterocolitis or sepsis in very low birth weight infants: a randomised controlled trial | |
RU2552039C2 (en) | Methods and lipid compositions aiding in intestinal flora development | |
US8105577B1 (en) | Prebiotic composition for increasing probiotic growth rate and activity | |
JP2012510800A (en) | Composition for use in low birth weight infants | |
US11278558B2 (en) | Synthetic composition for microbiota modulation | |
CN109451727A (en) | The composition and its preparation and application of probiotics and digestive ferment | |
US11541067B2 (en) | HMO compositions and methods for reducing detrimental proteolytic metabolites | |
Kumari et al. | Probiotics, prebiotics, and synbiotics: Current status and future uses for human health | |
US20160287702A1 (en) | Method of Improving Immune Function in Mammals using Lactobacillus Strains with Certain Lipids | |
CN111528479A (en) | Probiotics and prebiotics composition for relieving atopic dermatitis function and application | |
CN112237280A (en) | Dietary management of celiac disease and food allergies | |
Faujdar et al. | Role of probiotics in human health and disease: an update | |
RU2721257C2 (en) | Nutrient compositions and children's mixtures containing oligofructose for reducing the load of pathogenic bacteria in the intestines of infants and young children | |
CA2347891A1 (en) | Composition comprising micronutrients in combination with prebiotics, probiotics, and/or synbiotics | |
Karunaratne | Probiotic foods: Benefits to the cereal based Sri Lankan diet | |
EP4065146A1 (en) | Compositions and methods with a probiotic and a nutrient and/or mineral for the prevention or treatment of mastitis | |
Shirsath et al. | Role of Food Supplements in Gut Health | |
Gad et al. | Dietary intervention with edible film-coated multistrain probiotic Lacticaseibacilli in nondairy food matrices significantly increased the recovery of fecal viable Lacticaseibacilli and improved the performance of several colonic biomarkers among slightly malnourished preschool children | |
Haider | Probiotics and Prebiotics as Nutraceuticals | |
Das et al. | Metabolic and potential health benefits of nutraceuticals on gut microbiome | |
Gotteland et al. | Functional food in child nutrition | |
WO2022091075A1 (en) | Combination compositions of probiotics with fermented wheat germ extract and uses thereof | |
JP2013245174A (en) | Use of fructo-oligosaccharide for reinforcing production of il-27 in breast milk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |